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STRUCTURE DE LA THESE 
L’administration transdermique des peptides et des protéines offre de nombreux avantages 
par rapport aux injections parentérales et implants auxquels on recourt actuellement par manque 
d’alternatives.  Cependant, l’excellente fonction barrière de la peau empêche le passage de ces 
molécules par simple diffusion passive et conduit au développement de nombreuses stratégies 
permettant de la surmonter.  Parmi elles, la ionophorèse permet d’augmenter la perméation cutanée 
par le biais d’un faible courant électrique.  Le premier chapitre de la présente thèse permet de placer 
la ionophorèse dans le contexte de l’administration transdermique des molécules de nature peptidique 
ou protéinique en passant en revue les technologies actuellement disponibles ou en cours de 
développement, présentant leur principe, les mécanismes impliqués, leurs applications potentielles 
ainsi que leurs limitations. 
Bien que la ionophorèse soit une technique relativement ancienne, son application à 
l’administration transdermique de molécules telles que les peptides a moins de vingt ans et de 
nombreux aspects d’ordre mécanistique restent encore à explorer.  Dans ce contexte, le chapitre 2 
présente l’étude de l’effet de la séquence en acides aminés sur le transport ionophorétique d’une série 
de tripeptides dérivés de la structure des analogues de la gonadolibérine (LHRH) et de la 
somatostatine, administrés in vitro à travers de la peau d’oreilles de porc.  Les contributions relatives 
des deux mécanismes de transport que sont l’électroosmose et l’électromigration ont été déterminées 
pour chacun d’eux, ainsi que l’évolution de ces contributions en fonction des conditions 
expérimentales.   
Alors que de nombreuses relations structure - perméation quantitatives ont été établies dans 
le cas de l’administration transdermique passive (faisant intervenir des paramètres tels que la 
lipophilie et/ou la capacité à former des liaisons hydrogène), seuls quelques modèles reliant le 
passage ionophorétique de molécules à des paramètres de taille ont été décrits.  Le but du troisième 
chapitre est donc d’offrir une étude systématique et quantitative portant sur l’effet des propriétés 
physicochimiques des tripeptides étudiés (propriétés définies par des descripteurs tridimensionnels 
obtenus par modélisation moléculaire) sur leur transport ainsi que sur l’inhibition de l’électroosmose, 
phénomène observé lors de l’administration ionophorétique de plusieurs peptides. 
Enfin, l’évaluation de la faisabilité de l’administration transdermique par ionophorèse d’un 
analogue de la somatostatine (vapréotide) ainsi que celle d’un analogue de la LHRH (triptoréline) font 
l’objet des chapitres 4 et 5, respectivement.  Y est étudiée l’influence de différents paramètres tels que 
la densité du courant appliqué, la concentration du peptide, la présence d’ions compétiteurs ou le type 
de tissu, sur le passage transcutané ainsi que sur l’électroosmose. 
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INTRODUCTION 
La peau, chef-d’œuvre architectural 
D’une surface variant de 1.5 à 2 m2, la peau est un organe formé de deux tissus superposés, 
l’épiderme et le derme.  La couche la plus superficielle de l’épiderme est la couche cornée.  D’une 
épaisseur de 10 à 20 mm, elle est composée de 10 à 20 strates de cellules mortes (cornéocytes) 
remplies de filaments de kératine (70%) et de lipides (20%), arrangées à l’intérieur d’une matrice 
lipidique extracellulaire (ceramides 40%, acides gras libres 20%, cholesterol ~25%) de façon à former 
un assemblage similaire à un modèle de « briques et ciment » [1;2].  Directement sous la couche 
cornée, se trouve l’épiderme vivant, épithélium comprenant différents types de cellule (kératinocytes, 
mélanocytes, cellules de Langerhans et cellules de Merkel).  Quant au derme, c’est un tissu conjonctif 
principalement constitué de fibroblastes, fibres de collagène et fibres élastiques.  C’est lui qui contient 
les vaisseaux sanguins et les récepteurs sensoriels de la peau. 
 
Figure 1. Structures principales de la peau, ses annexes et les tissus sous-cutanés 
La peau et ses annexes (glandes sudoripares et sébacées, poils et ongles) remplissent de 
nombreuses fonctions visant à empêcher des facteurs de l’environnement, tels que les bactéries, 
l’abrasion, la chaleur, le froid et les substances chimiques, de perturber l’homéostasie de l’organisme.  
De par sa structure lamellaire unique, c’est la couche cornée qui confère à la peau l’essentiel de sa 
précieuse fonction barrière. 
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La peau, voie d’administration 
Si de nombreuses préparations pharmaceutiques sont appliquées sur la peau en vue d’une 
action locale, notamment pour le traitement des différentes dermatoses, d’autres sont destinées à 
avoir une action sur l’ensemble de l’organisme, via la circulation sanguine.  Ces systèmes, 
communément appelés patchs et définis par la Pharmacopée européenne sous le terme « dispositifs 
transdermiques », permettent de libérer au niveau systémique, des principes actifs qui sont mal 
absorbés par d’autres voies ou subissent une dégradation trop importante lors d’un premier passage 
hépatique.  Si le marché de cette forme galénique est important (3,9 milliards de dollars en 2002, 6,7 
milliards prévus pour 2007) [3], seuls une dizaine de principes actifs sont actuellement 
commercialisés, conséquence de l’excellente fonction barrière de la peau.  En effet, cette dernière 
limite la gamme des molécules susceptibles d’être administrées par un dispositif transdermique passif.  
En plus d’être pharmacologiquement puissant, l’agent thérapeutique doit répondre à certains critères 
d’ordre physicochimique tels qu’un poids moléculaire relativement faible (<500 Daltons), un coefficient 
de partage octanol-eau modéré (10<Ko/w<1000), et une solubilité aqueuse raisonnable (>1mg/ml) [4].  
Afin d’élargir le champ d’application thérapeutique de la voie transdermique à des molécules plus 
grandes et plus polaires, de nombreuses stratégies impliquant un transport actif des molécules à 
travers la peau ont été développées [5].  Parmi elles, la ionophorèse se distingue par son innocuité, 
son confort d’utilisation et son état de développement avancé [6]. 
L’ionophorèse, principe 
L’ionophorèse utilise un courant électrique de faible intensité (<0.5 mA/cm2) pour faciliter et 
contrôler le transport de molécules à travers la peau.  Un dispositif ionophorétique consiste en un 
patch contenant 2 électrodes (une anode et une cathode) que l’on connecte à une source de courant.  
Le principe actif contenu dans le patch est véhiculé par le biais de différents mécanismes de 
transport ;  en plus de l’électromigration (effet direct du champ électrique appliqué sur les espèces 
chargées), et de l’augmentation de la perméabilité cutanée induite par le courant, les molécules 
chargées positivement (placées dans le compartiment anodique) bénéficient d’un troisième 
mécanisme intitulé électroosmose, un flux de solvant qui résulte de la charge nette négative de la 
peau à pH physiologique.  Ce flux permet également le transport de molécules neutres. 
Outre les avantages propres à la voie transdermique, la ionophorèse offre la possibilité, en 
modulant l’intensité du courant appliqué, d’adapter le profil d’administration aux besoins de chaque 
patient ou chaque phase de traitement.  Cette caractéristique permet également une administration de 
type pulsatile, particulièrement profitable pour les principes actifs exerçant des effets 
pharmacologiques différents en fonction du profile d’administration (e.g., la gonadolibérine (LHRH) et 
ses analogues) ou pour ceux susceptibles d’induire un phénomène de tolérance (e.g., vasopressine).  
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Aussi, un traitement peut être rapidement stoppé en cas de nécessité par simple arrêt du courant, ce 
qui présente un avantage précieux par rapport aux implants. 
L’ionophorèse, application aux peptides et protéines 
Les propriétés physicochimiques des peptides et des protéines ainsi que leur forte 
susceptibilité à la dégradation, tant chimique qu’enzymatique, rendent leur administration difficile.  On 
recourt actuellement presque essentiellement à la voie parentérale, avec son lot d’inconvénients et la 
faible compliance qui en résulte.  Le développement d’alternatives efficaces et confortables pour le 
patient fait l’objet de très nombreuses recherches et représente un véritable défi.  De par leur taille et 
leur relative hydrophilie, ces composés ne sont pas à même de diffuser passivement à travers la peau 
et d’atteindre ainsi la circulation systémique.  Cependant, leur caractère souvent chargé fait de ces 
molécules de bons candidats à la ionophorèse. 
L’application de la ionophorèse à l’administration de peptides pharmacologiquement actifs a 
commencé à la fin des années quatre-vingts et a suscité beaucoup d’intérêt [7].  De nombreux 
peptides tels que la protiréline (PTH) [8], l’angiotensine [9], l’octréotide [10], la gonadolibérine (LHRH) 
et ses analogues [11-15], l’arginine-vasopressine [16], la calcitonine [17] et l’hormone 
parathyroïdienne [18] ont été étudiés et administrés avec succès, tant in vitro que in vivo.  
L’extraordinaire potentiel commercial que représente l’insuline conduit inévitablement à une recherche 
considérable portant sur son administration par cette voie [19].  De par certaines propriétés 
défavorables, tant physicochimiques (e.g., poids moléculaire ~6000 Da, charge négative) que 
pharmacodynamiques (doses élevées requises pour effet pharmacologique), son administration par 
ionophorèse s’avère extrêmement difficile.  Cependant, si les protéines de poids moléculaire élevé 
sortent du spectre d’application de la ionophorèse, l’administration de peptides spécifiques se révèle 
être un objectif tout à fait réalisable. 
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Résumé 
L’administration transdermique est à la pointe de la recherche dans le domaine du 
développement de méthodes non-invasives pour l’administration systémique des principes actifs de 
structure peptidique ou protéinique résultant de la révolution biotechnologique.  De nombreuses 
approches ont été proposées pour surmonter l’excellente fonction barrière de la peau; alors que 
certaines agissent simplement au niveau de la drogue ou en augmentant de façon transitoire la 
perméabilité de la peau, d’autres sont conçues dans le but d’outrepasser ou même d’enlever la 
couche superficielle de la peau.  Cet article passe en revue les technologies qui font actuellement 
l’objet d’investigations, en allant de celles encore aux prémices de leur développement, comme 
l’administration assistée par le laser, aux techniques plus abouties ayant déjà conduit à des produits 
commercialisés (les systèmes d’injection à pression), en passant par celles dont la faisabilité a déjà 
été démontrée, comme les microaiguilles.  Les principes, les mécanismes impliqués, les applications 
potentielles, les limitations ainsi que la sécurité d’utilisation sont discutés pour chacune des 
approches, et les dispositifs les plus avancés sont décrits. 
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Abstract 
Transdermal delivery has been at the forefront of research addressing the development of  non-
invasive methods for the systemic administration of peptide and protein therapeutics generated by the 
biotechnology revolution.  Numerous approaches have been suggested for overcoming the skin’s 
formidable barrier function; while certain act simply on the drug formulation or transiently increase the 
skin permeability, others are designed to by-pass or even remove the outermost skin layer.  This 
article reviews the technologies currently under investigation, ranging from those in their early-stage 
development, such as laser-assisted delivery to others, where feasibility has already been 
demonstrated, such as microneedle systems, and finally more mature techniques that have already 
led to commercialisation (for example, velocity based technologies).  The principles, mechanisms 
involved, potential applications, limitations and safety considerations are discussed for each approach, 
and the most advanced devices in each field are described. 
Keywords:  Transdermal drug delivery, peptide and protein delivery, iontophoresis, electroporation, 
sonophoresis, microneedles, encapsulation, jet-injectors, stratum corneum ablation 
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1. PEPTIDE AND PROTEIN DELIVERY 
Revolutionary advances in biotechnology have given rise to numerous protein and peptide 
entities with therapeutic potential.  One of the major challenges to the successful clinical use of these 
“biotech” molecules is their efficient and targeted delivery to the site of action.  Presently, parenteral 
delivery is the most routinely employed method for administering polypeptide agents, which are 
otherwise completely destroyed when given orally.  These compounds often have short plasma half-
lives, need frequent injections and are, therefore, associated with poor compliance.  In recent years, 
alternative and more patient-friendly modes of drug delivery have been extensively investigated. 
2. TRANSDERMAL DELIVERY 
Over the past few decades, the skin has generated a great deal of interest as a portal for the systemic 
delivery of drugs [1].  The potential advantages of this mode of administration have been well 
documented [2].  The worldwide transdermal market is currently worth more than US$ 4 billion, yet is 
based on only thirteen drugs.  This rather limited number of transdermal drugs is explained by the 
skin’s excellent barrier function, which is accomplished entirely and quite remarkably by the outermost 
few microns of tissue, the stratum corneum: often referred to as a “brick and mortar” structure [3].  
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Figure 1.  Major skin structures. 
In addition to being pharmacologically potent, a therapeutic agent must possess a balance of 
physicochemical properties that render it permeable: a relatively low molecular weight (<500 Daltons), 
a moderate octanol-water partition coefficient (10 <Ko/w<1000), reasonable aqueous solubility 
(>1mg.ml-1) and modest melting point (<200°C) [4].  
Most, if not all, peptides and proteins, being large and hydrophilic, do not satisfy these criteria. 
Yet, the transdermal delivery of these potent therapeutic agents is of particular interest, since 
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percutaneous administration overcomes many of the problems associated with conventional therapy.  
Hence, to expand the range of drugs that can be delivered transdermally, and to include peptides and 
proteins, a number of enhancement technologies are under investigation. 
3. FROM SKIN SURFACE TO SYSTEMIC CIRCULATION 
Before being taken up by blood vessels in the upper papillary dermis and prior to entering the 
systemic circulation, substances permeating through the skin must cross the stratum corneum and the 
viable epidermis.  There are three possible pathways leading to the capillary network: across the 
continuous stratum corneum (SC), through hair follicles and their associated sebaceous glands, or via 
sweat ducts.  Although, the “as-the-crow-flies” diffusion distance across the SC is no more than 10-15 
mm, the actual diffusional pathway may be upto fiftyfold greater, depending on the route taken (Fig.1).  
While crossing the viable skin layers, peptidic drugs can undergo extensive enzymatic degradation [5-
7]; numerous proteases (including endopeptidases and exopeptidases) have been detected in the 
skin, both in the dermis and the epidermis [6-8].  However, as a result of the rapid uptake of 
penetrants into the general circulation on arrival in the highly vascularized dermal papillary layer, 
peptide/protein metabolism is most likely to occur during passage through the epidermal layer [9].  
Although this phenomenon may appear to mitigate one of the benefits of transdermal delivery 
(avoidance of gastrointestinal and hepatic enzymatic metabolism), the extent of epidermal catabolism 
is of course dependent on (a) the application area (e.g., patch size), and (b) the rate of epidermal 
transport - parameters that are optimized in the design of “active” transdermal systems.  In addition, 
peptide formulations can also be designed to incorporate specific enzyme inhibitors [10, 11].  
Parenthetically, certain energy-driven enhancement techniques may also impact on enzyme activity, 
as reported for ultrasound, which is suggested to deactivate certain skin enzymes [12, 13]. 
This article reviews the current state of transdermal peptide drug delivery technology. The 
strategies are classified as a function of the manner in which they overcome the skin barrier (Fig. 2).  
The approaches range from formulation optimisation, to energy-driven techniques including 
electrically-assisted transport, through to methods designed to enhance drug delivery by by-passing 
the barrier or even by removing it. 
4. FORMULATION OPTIMISATION 
Peptide drugs, which are hydrophilic and often charged molecules, pass through lipophilic 
membranes such as the SC with some difficulty, if at all.  To counteract this, there are two main 
approaches available to the formulation scientist: (a) the use of chemical enhancers to transiently 
modify the SC permeability (i.e. render the SC more “leaky” towards hydrophilic molecules), and (b) 
modification of the therapeutic molecule to render it more hydrophobic and therefore “acceptable” to 
the membrane.  The latter strategy involves either chemical derivatization, or encapsulation within a 
lipophilic core. 
Chapitre 1  11 
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Figure 2.  Current strategies for transdermal drug delivery. 
Italicized legends signify those technologies, which are still in their infancy or are unlikely to find an application in 
peptide and protein delivery in the near future. 
4.1 Chemical penetration enhancers 
There exists an extensive literature on penetration enhancers, their mechanisms of action and 
effects on the skin, and their impact on the permeation of applied molecules [14, 15].  These 
compounds appear to act by disrupting or altering the ordered lipid structure of the SC.  Whereas 
numerous studies on the passive delivery of peptides and proteins with chemical enhancement were 
conducted during the 80’s and 90’s [16], research in this area has somewhat “run out of steam”, 
primarily for two reasons.  First, while low MW therapeutics usually tolerate formulation with these 
permeation enhancers, proteins are less comfortable in the company of these aggressive chemicals.  
The second and most important reason concerns safety.  Unfortunately, for most enhancers, activity is 
closely correlated with irritation, rendering them clinically unacceptable [17]. Thus, because of the 
extremely low permeability coefficients of peptide and protein drugs - readily predicted from their 
hydrophilicity and molecular size - the magnitude of enhancement required to ensure delivery of 
pharmacologically effective concentrations is expected to be beyond the capability of chemical 
enhancers tolerated by the skin. 
4.2 Chemical modification 
Whereas improved intestinal absorption through chemical modification with various fatty acids 
has been reported for some peptide and protein drugs, the application of this approach to transdermal 
delivery is quite new.  A few research groups have studied the cutaneous delivery of derivatives of 
peptides such as the vasoactive intestinal peptide [18] and interferon a [19].  The absorption of 
palmitoyl derivatives of interferon a (p-IFNa) into the viable layers of human breast skin was eightfold 
greater compared to the parent peptide, suggesting that this approach might find an application in 
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topical delivery.  The enhancement potential in transdermal delivery is less obvious, given that only a 
two-fold increase in the percutaneous absorption of p-IFNa was observed.  These results must also be 
treated with caution given the surprisingly elevated passive permeability of the parent polypeptide 
(1.47 ng/cm2/h). 
Finally, one must question whether a modest improvement in delivery is sufficient to warrant the 
additional regulatory complexities concomitant with the prodrug strategy.  During drug development, 
the chemically-modified derivative will have to undergo – as for the parent molecule - extensive 
toxicological testing in addition to the suite of developmental investigations. 
4.3 Encapsulation technologies 
Encapsulation consists of the entrapment of drug within delivery systems such as microspheres, 
liposomes and nanoparticles.  Liposomes, typically consisting of phospholipids and cholesterol, are 
thermodynamically stable vesicles with an aqueous core and at least one surrounding bilayer.  
Niosomes, analogues of liposomes, are non-phospholipid vesicles formed by the self-assembly of 
nonionic surfactants in an aqueous dispersion.  Niosomes and classical liposomal systems have been 
found to be effective in forming drug reservoirs in the upper layers of the skin, for local therapy.  The 
controlled topical delivery of cyclosporin A [20] and interferon a [21] has been studied: ≤ 1µg/cm2 of 
liposomally encapsulated interferon a was found in human skin after a 24 hour in vitro application.  
However, the use of liposomes and niosomes for the systemic delivery of macromolecules across the 
skin has not been successful to-date. 
Transfersomes are ultradeformable carriers that are claimed to be driven across the skin by the 
transdermal hydration gradient [22].  They are suggested to be sufficiently flexible to pass through 
pores appreciably smaller than their own size (200-300 nm).  Insulin-loaded transfersomes were 
reported to induce a modest 15% decrease of blood glucose concentration in healthy human 
volunteers [23], a response which is unlikely to provoke a therapeutic effect in diabetic patients. 
Ethosomes are phospholipid vesicular systems containing ethanol in relatively high 
concentrations.  According to Touitou et al., ethanol fluidises both the ethosomal lipids and the SC 
lipid mortar; the soft, malleable vesicles then penetrate through the disorganized lipid bilayers [24].  
Several studies have been conducted with non-peptidic drugs such as testosterone [25], 
trihexyphenidyl hydrochloride (currently used for the treatment of Parkinson’s disease) [26] and 
zidovudine (an antiviral agent) [27].  As is often the case, insulin, because of its huge potential market, 
was the first peptide studied.  The effect of a transdermal insulin formulation on blood glucose levels 
was investigated in vivo in normal and diabetic rats.  Despite the significant decrease (≤ 60%) in blood 
glucose levels achieved in both normal and diabetic rats [28], it is clear that a corresponding effect in 
humans would require significant scaling-up, which remains to be demonstrated. 
Finally, although encapsulation might be considered to offer some protection from cutaneous 
enzymes, the point at which the drug leaves its ‘protective capsule’ during its passage through the 
tissue has yet to be determined.  Moreover, any benefits offered are likely to be offset by formulation 
stability issues. 
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5. ENERGY DRIVEN METHODS 
5.1 Iontophoresis 
Iontophoresis is a century-old technique developed to deliver charged molecules through the 
skin at an enhanced rate via application of a small electric current (£ 0.5 mA/cm2).  The drug reservoir 
on the surface of the skin is in contact with an electrode of the same charge as the solute, connected 
to a grounding electrode and a power supply. In addition to electromigration (direct effect of the 
applied electric field on the charged species), and current-induced modification of passive skin 
permeability, positively charged compounds (present in the anodal compartment) benefit from a third 
transport mechanism called electroosmosis, a convective solvent flow which is a consequence of the 
skin’s net negative charge at physiological pH.  This flow also enhances the transport of neutral 
compounds. 
A feature of iontophoresis, which distinguishes it from other enhancement technologies, is that it 
acts primarily on the molecule itself.  The technique does not simply involve passive transport of the 
drug following barrier disruption: the driving force comes from the applied electric field and is not solely 
dependent upon the concentration gradient, as in passive delivery. Hence, by modulating the current 
applied, iontophoresis allows adaptation of the delivery input rate and profile to the needs of each 
patient or phase of treatment, and offers the possibility of pulsatile drug delivery.  Although the 
advantages of “constant” or “sustained” plasma concentrations have long been endorsed, there are a 
number of therapies which benefit from the conventional “peak and trough” plasma profiles.  
Moreover, certain peptides such as human parathyroid hormone (PTH) and luteinizing hormone-
releasing hormone (LHRH) have distinct, and often opposing, pharmacological effects depending on 
their delivery profile.  LHRH, for example, must be administered as a bolus every 60-90 min to treat 
female infertility, but must be given as a continuous infusion in the treatment of certain cancers.  
Pulsatile delivery is also desirable where downregulation and tolerance may be a concern, as 
demonstrated for vasopressin [29].  Considerable interest has been and continues to be shown in the 
iontophoretic delivery of therapeutic peptides and proteins which, given their often charged character, 
are good candidates for this technology.  Numerous peptides including Thyrotropin releasing hormone 
(TRH) [30], angiotensin [31], octreotide [32], luteinizing hormone releasing hormone (LHRH) and 
analogues [33-37] arginine-vasopressin [38], calcitonin [39], human parathyroid hormone (1-34) [40] 
and insulin [41] have been studied.  Many of these peptides have also been the subject of mechanistic 
investigations, and electroosmosis has been proposed to be the predominant mechanism governing 
the iontophoretic transdermal delivery of large (molecular weight ³ 1000 Da) cationic peptides [42].  
However, peptides containing closely juxtapositioned cationic and lipophilic residues are able to inhibit 
this transport mechanism, and hence their own transport, by altering the permselectivity properties of 
the skin when iontophoresed [43-48].  This inhibition may be considered as a limitation in the 
iontophoretic transdermal delivery of certain peptide drugs containing this structural motif.  
Nevertheless, leuprolide, a synthetic nonapeptide analogue of LHRH containing D-Leu-Leu-Arg at 
position 6-8 (corresponding to the mentioned structural signature) has been successfully delivered in 
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vivo in humans to produce a peak LH response similar to that by subcutaneous injection [49].  Other in 
vivo studies have also compared the delivery profile obtained after iontophoresis, to that measured 
after conventional needle injections, to demonstrate the potential of this administration route.  Such an 
example is illustrated in Figure 3 for the delivery of the growth hormone releasing factor GRF (1-44), 
where steady-state plasma GRF levels after iontophoretic delivery are greater and more sustained, 
relative to those following intravenous and subcutaneous injections [50].   
 
 
Figure 3.  Plasma levels of growth hormone 
releasing factor (GRF) in response to 
transdermal iontophoretic (1 mg/g; 0.17 mA/cm2; 
5 cm2 patch), intravenous (10 mg/kg; 0.025 mg/ml) 
and subcutaneous (10 mg/kg; 0.025 mg/ml) GRF 
administration to the guinea pig.   
Reprinted from Ref. [50], with permission from 
Elsevier. 
 
 
Not surprisingly, the iontophoretic delivery of insulin has provoked much attention.  However, 
while the delivery of regular insulin by iontophoresis might be sufficient to treat a small mammals, the 
best deliveries achieved, even with monomeric insulin analogues [51], are still 1-2 orders of magnitude 
below those necessary to match the basal secretion level in humans [41]. 
Owing to the advanced nature of transdermal iontophoretic research and development, these 
systems are relatively well-characterized and understood.  For example, the recently launched 
LidoSite™ device (Figure 4; Vyteris Inc., NJ, USA) [52] for local anaesthesia and the IONSYS™ 
system for fentanyl delivery (Alza Corp., CA, USA; 
currently awating final FDA approval) offer 
iontophoretic platforms, which can be potentially 
adapted and customized to the local and systemic 
iontophoretic administration of peptide drugs. 
 
 
 
Figure 4.  LidoSite™, an iontophoretic delivery system 
for lidocaine (Vyteris Inc., NJ, USA). Reproduced with 
permission from Ref. [52]. 
5.2 Electroporation 
First used for the introduction of DNA material into cells in vitro, the use of electroporation for 
transdermal delivery was suggested about 10 years ago.  Unlike iontophoresis, which employs small 
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currents (transdermal voltages £ 10V) for relatively long periods of time (many minutes to hours), 
electroporation involves exposure of the skin to relatively high voltages (approx. 100-1000 V) for short 
times, typically 1 to several hundred milliseconds, which in turn create intense electric fields across the 
thin stratum corneum.  Molecular transport through transiently permeabilized skin is thought to result 
from a variety of mechanisms: enhanced diffusion through the aqueous pathways produced in the lipid 
bilayers, electrophoretic movement (for charged species) and, to a small extent, electroosmosis [53]. 
A study investigating insulin delivery demonstrated that while less than 0.6 mg/cm2 insulin was 
transported across porcine epidermis after electroporation (100 V, 1 Hz, 1 ms pulse for 10 min.), 
around 13 mg/cm2 (~0.33 U/cm2) reached the receptor compartment when delivered from a formulation 
containing phospholipids under the same electroporation regime [54].  The treatment of a diabetic 
patient (36U, daily) is obviously unfeasible with such an input, but this 20-fold enhancement in 
transport demonstrates the potential for synergistic combination of electrically-assisted and chemical 
technologies. 
Transdermal heparin transport across human skin in vitro was possible at therapeutic rates with 
electroporation, whereas the low-voltage iontophoretic flux with the same time-averaged current was 
an order of magnitude lower [55].  Similarly, electroporation significantly enhanced the flux of human 
parathyroid hormone (1-34) in comparison to iontophoresis [40], suggesting that high-voltage pulsing 
creates transient changes in skin permeability, which do not occur during iontophoresis. 
However, while electrically-assisted skin delivery via iontophoresis has been widely investigated 
in humans and shown to be safe and well-tolerated, very few human studies have been conducted 
with electroporation.  In electrochemotherapy investigations, where electric pulses greater than 1000 V 
were applied to the skin of melanoma patients to facilitate the chemotherapeutic treatment of tumour 
nodules, muscle contractions and mild pain were reported during each pulse in addition to a transient 
erythema [56].  Although these unwanted side effects subsided after the pulse, further investigation is 
required to determine whether transdermal drug delivery by electroporation is clinically feasible. 
5.3 Sonophoresis 
Sonophoresis (or phonophoresis) is defined as the movement of drugs through intact skin and 
into soft tissue under the influence of an ultrasonic perturbation [57].  Low-frequency ultrasound 
(frequencies below 100 kHz) has been demonstrated to induce the greatest transdermal transport 
enhancement [58, 59].  Numerous studies have been devoted to understanding the mechanisms of 
sonophoresis [60-63].  Acoustic cavitation, the formation and collapse of gaseous cavities, plays the 
dominant role in low-frequency sonophoresis [64, 65], although significant stratum corneum lipid 
removal has also been reported [60] and may explain the increased skin permeability observed during, 
and after, low-frequency ultrasound application. 
Mitragotri et al. reported the delivery of insulin (6000 Da), γ-interferon (17000 Da), and 
erythropoietin (48000 Da) in vitro, across human epidermis using ultrasound (20 kHz, 100-ms pulses 
applied every second for 4 hours).  The insulin flux achieved was shown to be sufficient to treat a 
diabetic subject assuming a transdermal patch area of 40 cm2 containing insulin at a concentration of 
100 U/ml [66, 67].  Yet, despite this optimistic calculation, a sonophoretic insulin patch has not been 
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developed, highlighting the challenge of extrapolating from in vitro studies to clinical scenarios.  
Similarly, a 50% reduction in blood glucose subsequent to low-frequency insulin sonophoresis in rats 
(Fig. 5;[68]), while offering a valid “proof-of-concept”, does not guarantee that a similar approach will 
work in an adult diabetic patient. 
 
 
 
 
Figure 5.  Blood glucose levels in rats after 
intramuscular injection of insulin 0.5 U and 
sonophoresis of insulin (I = 2.5 Watts/cm2, teff = 6 
min., tUS = 15 min., ton = 3.2 s.).  Reprinted from Ref. 
[68] with permission from Elsevier. 
I = pulse intensity during ultrasound application; teff: total 
duration of ultrasound exposure during treatment time, tUS; ton: 
duration of each ultrasound pulse; tUS: total treatment time 
during which pulsed ultrasound was applied. 
 
On the whole, research into peptide and protein delivery using this technique has been limited, 
although a technological platform for potential applications clearly exists.  An ultrasonic skin 
permeation device (SonoPrepÒ, Sontra Medical, MA, USA), awaiting FDA-510k clearance, enables 
rapid delivery of lidocaine and local skin anæsthesia within five minutes after a brief skin pretreatment 
(55 kHz, ~10 sec pulses) [69].  Nevertheless, the feasibility of such a system at higher intensities and 
over longer periods needs to be examined.  Singer et al. [70] noted minimal urticarial reactions after 
low-intensity ultrasound, but higher-intensity sonophoresis produced significant thermal injuries similar 
to second-degree burns.  Hence, as with other energy-based technologies, sonophoresis exhibits a 
window of parameters within which safe application can be practiced; whether or not this window 
encompasses macromolecular delivery remains to be seen. 
6. MINIMALLY-INVASIVE SYSTEMS 
Numerous "minimally-invasive" strategies for transdermal drug delivery have been described, 
and recently reviewed by Down and Harvey [71].  Often, these technologies are the subject of patent 
claims but their therapeutic utility remains unsubstantiated.  In this section, we have selected systems, 
which have been designed, in effect, to "by-pass" the skin barrier without blatant SC removal.  
Microneedles and velocity-based injectors, because of their ability to breach the SC, offer drug 
delivery platforms that may be suitable for higher MW drugs. 
6.1 Microneedles 
Over the last few years, advances in microelectronics have been innovatively applied to a 
variety of health care-related products – from miniaturized diagnostic tools (for example, biosensors) 
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to microdevices for therapeutic drug administration.  Microneedles (µm dimensions) in various 
geometries and materials (silicon, metal, and polymer) have been produced using recently developed 
microfabrication techniques.  These microneedle arrays are applied to the skin surface such that they 
pierce the epidermis (devoid of nociceptors), creating microscopic holes through which molecules can 
be transported to reach the upper dermal layers.  The microneedle arrays penetrate to the dermal 
microcirculation and allow systemic drug delivery, but are short enough to avoid stimulation of dermal 
nerves. 
Solid microneedles either puncture the skin prior to the application of drug contained in a patch 
system, or are pre-coated with drug and then inserted into the skin.  The first approach implies a two-
step application procedure, which might seriously limit its ease-of-use, whereas the second presents 
the disadvantage of being “surface-limited”: that is, the total amount of drug which can be loaded, and 
hence delivered, is limited by the total microneedle surface.  Microneedles containing a hollow bore 
provide an alternative to solid structures and offer the possibility of transporting drugs through the 
interior of well-defined needles by diffusion or, for more rapid rates of delivery, by pressure-driven 
flow. 
Both solid and hollow microneedles have been used to deliver insulin in vivo in diabetic rats.  
McAllister et al. demonstrated a 70% reduction in blood glucose 5 hours after a 30-min microinfusion 
of insulin at a pressure of 14 psi using hollow microneedles [72].  Solid metal microneedles also 
increased insulin delivery and lowered blood glucose levels by as much as 80% when a 105 
microneedle array was inserted into the skin for 10 minutes and removed before the topical application 
of an insulin solution for 4 hours [73].  Such a reduction of blood glucose in rats corresponds to an 
insulin dose of 1.6-4.1 mU, a dose significantly lower than the ~36 U of insulin required by a typical 
diabetic patient each day (12U tds) [67].  Furthermore, the significant lag time between application and 
therapeutic effect is also of some concern.  Recent in vivo studies, in hairless guinea pig, investigated 
the transdermal delivery of desmopressin using the MacrofluxÒ system (Alza Corporation, CA, USA) 
[74, 75].   
ba c
 
Figure 6.  MacrofluxÒ patch technology (Alza Corporation, CA, USA)  
A) The patch comprising the coated microneedle array affixed to an adhesive backing. Reprinted from Ref. [74], 
with permission from Elsevier. 
B) The patch loaded on the disposable retainer ring and the reusable applicator.  Reprinted from Ref. [74], with 
permission from Elsevier. 
C) Scanning electron photomicrograph of an array of microprojections (L: 330 μm) and a conventional 25-gauge 
needle. Reprinted with permission from Ref. [77]. 
 
A
 
C
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The MacrofluxÒ system (Figure 6), incorporates a 2 cm2 array of titanium microneedles, which 
can be coated with drug for rapid bolus administration, or used in combination with a drug reservoir for 
continuous passive or iontophoretic applications [75]. When coated with desmopressin, these 
microneedles allowed pharmacologically relevant amounts of this synthetic peptide hormone to be 
delivered, with a bioavailability as high as 85% (c.f., oral and nasal bioavailability of 0.1% and 3.4%, 
respectively) in human volunteers (Figure 7; [76]).  Average systemic deliveries of desmopressin 
ranged from 17 to 34 mg after 5 or 15 minute application time, which is significantly more than the 1 to 
4 mg recommended daily by subcutaneous, intramuscular or intravenous injection in the management 
of primary nocturnal enuresis.  This device has also demonstrated promising results with vaccines 
[77].  
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Figure 7.  Comparison of serum desmopressin concentrations following administration by intravenous 
injection (11 mg), or via a coated microneedle array (82 mg) (microneedle array contact time = 5 min.).  
Reprinted from Ref. [74], with permission from Elsevier. 
 
Microneedles have been described as painless, inducing neither erythema nor edema [78, 79].  
In addition, the µm-scale holes produced are significantly smaller than those created by hypodermic 
needles [80].  However, the reversibility and the consequences of chronic applications of these arrays 
remain to be studied.  The immediate concern with this technology is the possibility of fractured needle 
fragments remaining in the skin, although it has been reported that the majority of silicon microneedles 
remained intact after insertion into skin [78].  Nonetheless, the potential risk of residual material in the 
skin after treatment needs to be examined.  In this respect, metal and polymer microneedles offer 
significant advantages: in addition to being more robust, less expensive and easily scalable for mass 
production, many metal and polymer (especially biodegradable) materials have established safety 
records in medical devices, whereas silicon is a new and relatively untested biomaterial [72].  
Microneedles, essentially a hybrid of hypodermic needles and transdermal patches, provide an 
interesting and promising alternative, currently being pursued by several companies and resulting in 
an impressive number of patents. 
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6.2 Velocity-based technologies 
A jet injector produces a high-velocity jet (>100 m/s) that penetrates the skin and delivers drugs 
into the epidermis, intradermally, subcutaneously, or intramuscularly by means of a compression 
spring or compressed air [81].  Most commercial devices produce a single jet for drug delivery through 
an orifice of around 150 mm in diameter.  These systems resemble a pen, as illustrated in Figure 8. 
 
 
 
 
 
 
Figure 8.  Medi-Jector Visionä (Antares Pharma 
Inc., PA, USA), Needle Free Insulin Injection 
System.  
Reproduced with permission from Antares Pharma 
Inc. 
 
Interest in these systems as an alternative to the routine use of needles in vaccination has partly 
stemmed from the increasing incidence of injection-associated, blood-borne pathogen infections 
(hepatitis B, hepatitis C and human immunodeficiency viruses) in developing countries.  An 
exhaustive, web-based document [82] underlines the attention attracted by this technology. 
One category of jet injectors has been developed for the delivery of liquid protein formulations.  
Figure 9 illustrates the similarity of a profile obtained with one such system to that measured after a 
conventional needle injection in a human study.   
 
 
 
 
 
 
Figure 9.  Comparison of serum ganirelix 
concentrations following administration of 
Orgalutranâ by subcutaneous injection or via 
the Medi-JectorÒ device. 
Adapted from Ref. [117] with permission of Oxford 
University Press/Human Reproduction. 
 
Numerous devices have been on the market for several years.  As shown in Table 1, most of the 
marketed devices are dedicated to insulin and human growth hormone (hGH).  Today, compounds 
such as pegylated interferon alpha (Pegasysâ), erythropoietin and antibodies are also receiving 
attention for delivery via this system [83]. 
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Table 1. A representative selection of commercially available needle-free jet injectors. 
Device tradename Marketed by Drug (proprietary name) References 
VitajetÔ Bioject Insulin [81] 
BiojectorÒ Bioject Vaccines and other liquid medications  
Cool.clickÔ Serono hGH (SaizenÒ) [118] 
SerojetÔ Serono hGH (SerostimÒ)  
Medi-jectorÒ Antares Pharma Insulin, hGH, ganirelix (OrgalutranÒ) [117, 119] 
ZomajetÒ Ferring hGH [89] 
Genotropin ZipTipÔ Pfizer hGH (GenotropinÒ) [88] 
 
 
A second category of jet injectors allows Transdermal Powdered Delivery (TPD), for which the 
therapeutic compound is formulated as a powder.  Fine drug particles (20-100 mm in diameter) are 
thus accelerated in a supersonic flow of helium gas to penetrate the outer layers of the skin.  The 
powder injection delivery of salmon calcitonin (s-CT) was studied in rabbits in vivo using the 
PowderJectÒ device (PowderJect Pharmaceuticals plc., recently acquired by Chiron Corporation, CA, 
USA).  The administration of 1 mg of powder containing 40 mg of s-CT using a pressure of 60 bar led 
to an 11% decrease in serum calcium concentration [84].  When the same system was used to deliver 
human insulin to rats, blood glucose concentration was found to decrease by approximately 40% [84].  
Here again, a corresponding effect in humans would require significant scaling-up, which remains to 
be demonstrated.  This technology also allows targeting of DNA and protein vaccines to the epidermis, 
a skin layer which is populated by numerous antigen presenting cells, and therefore offers the 
possibility of needle-free immunization [85]. 
Although dry powder formulations are better suited to storage than solutions, a significant 
limitation of the PowderJectÒ technology is the upper limit on the dose that can be delivered, which is 
approximately 6 mg.  Moreover, the powder must survive the high stress of a gas jet within the device 
and the ballistic impact with the skin at supersonic velocities.  Finally, the dispersed fine particles must 
then dissolve and diffuse into the skin in order to act locally or to reach the systemic circulation. 
With the exception of the PowderJectÒ system, which was reported as being painless during the 
course of Phase I and Phase II clinical studies [84], jet injectors are recognized for their propensity to 
cause pain and bruising [86].  Thus, despite the reported bioequivalence between needle-free devices 
and needle injection, the superiority of jet injectors in terms of comfort and compliance is, according to 
several studies, far from obvious [87-92].  Hence, the undisputable advantage of this technology, 
compared to conventional syringe injection, lies in the absence of a (visible) needle, which may be of 
benefit to children and needle-phobic patients, and in mass injection programs where the risk of 
contamination may be an important concern. 
Since their introduction to the market eight years ago, jet injectors have not revolutionized the 
delivery of insulin in diabetic patients, who for the most part, continue to use conventional injection 
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systems.  This suggests that this innovative technology might not be the choice alternative to the 
parenteral route for delivering peptides and proteins.  However, it seems likely to play a key role in 
tomorrow’s vaccination strategies. 
7. STRATUM CORNEUM ABLATION 
The simplest method for overcoming the barrier imposed by the stratum corneum is to remove it.  
This can be achieved, for instance, by repeated application of adhesive tape to the skin surface.  
However, for a number of reasons - including those of convenience, reproducibility, and patient 
compliance, it is difficult to envisage the routine clinical use of such an approach.  Laser-assisted 
ablation and SC ablation by suctioning are perhaps more realistic approaches but are also likely to be 
associated with patient compliance issues.  Alternative, more recent technologies currently under 
investigation include microscissioning (see section 9.3, below) and radiofrequency thermal ablation. 
7.1 Suction ablation 
Suction ablation uses a vacuum to produce a small blister (5-6 mm in diameter), the upper 
surface of which is excised to reveal a portal for entry of drugs into the dermal circulation [71].  The 
feasibility of this technique was tested in seven healthy volunteers using the antidiuretic peptide 1-
deamino-8-D-arginine vasopressin (DDAVP), in whom the bioavailability was reported to approach 
100 % [93].  In a separate study using an oxytocin antagonist, antocin, therapeutic blood levels were 
measured in healthy volunteers one hour after administration [94].  This technology has resulted in a 
commercial product, CellpatchÒ (Epiport Pain Relief AB, Sweden), which incorporates all the 
components of the process: suction device, epidermatome (to remove the blister), and a drug 
reservoir.  Clinical studies have tested the feasibility of transepidermal morphine delivery by this 
methodology in normal healthy volunteers [95] and in postoperative patients [96].  The studies 
reported an absence of pain (possibly due to the concomitant delivery of morphine?), erythema and 
scar formation.  Regeneration of the epidermis occurred one week after removal of the system.  
However, the vacuum removal of the epithelium caused pronounced hyperaemia in the de-
epithelialised dermis and the sites showed slight, fading pigmentation even 3 months after treatment, 
suggesting that this procedure may not be appropriate for the treatment of chronic disease.  In view of 
this drawback, and given the absence of published work since 1996, suction ablation is unlikely to be 
a technology of choice in the near future. 
7.2 Laser ablation 
In this approach, the high energy of the laser creates pores in the skin that permit the transit of 
drug through the SC from, for example, a topically applied patch or gel [71].  There are two optimal 
wavelengths at which skin ablation can be achieved: a wavelength absorbed by tissue proteins (2940 
nm) and one absorbed by tissue water (mid-infrared; 2790 nm).  During laser irradiation, the energy is 
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absorbed by the components of the skin in the form of vibrational heating.  Water within the irradiated 
area of the skin quickly reaches its boiling point, and the resulting vapour pressure elicits a 
microexplosion that results in ablation, as the tissue vaporizes.  The rapid loss of energy from the 
ablated site protects the surrounding skin tissues from heat-induced damage.  The level of energy 
imparted to the skin permits removal of the stratum corneum in a controllable fashion. 
The erbium:YAG laser (2940 nm), currently used in plastic surgery for the resurfacing of 
rhytides, scars, photodamage, and melasma [97] was demonstrated to greatly enhance 5-fluorouracil 
permeation across mouse skin in vitro [98].  The only study performed with a peptide showed a 2.1-
fold increase in g-interferon transport across pig skin using an erbium:YSGG laser (2790 nm) [99]. 
While laser-assisted drug delivery may be technically feasible, many questions regarding safety 
remain unanswered [71]; for the moment, the utility of this technology is likely to be limited to niche 
applications within hospital settings, notably because of the elevated cost of medical lasers. 
7.3 Radiofrequency thermal ablation 
Radiofrequency (RF) thermal ablation is a well-known and effective technology for 
electrosurgery and ablation of malignant tissues.  A thin electrode is placed directly into the tumor; 
application of RF energy results in the passage of an alternating frequency current from the tip of the 
electrode into the surrounding tissue.  The movement of ions, which attempt to follow the change in 
the direction of the alternating current, results in frictional heating of the tissue, producing coagulative 
necrosis and cell ablation [100].  This technique has only recently been adapted for use as a physical 
method to enhance drug transport across the skin.  A closely spaced array of tiny electrodes is placed 
against the skin while an alternating current at radio frequency is applied to each of the 
microelectrodes.  This forms microchannels in the outer layer of the skin through the ablation of cells.  
The ViaDermÔ RF-microchannel generator (Transpharma Ltd, Israel) consists of 140 stainless steel 
electrodes (length: 100 mm; diameter: 40 mm) spaced 1 mm apart.  When a certain pressure is applied 
to the device in contact with the skin, the RF-generator is activated momentarily, resulting in thermal 
ablation.  Percutaneous penetration studies were performed with granisetron hydrochloride and 
sodium diclofenac in vivo in rats, and in vitro using full thickness porcine ear skin.  The apparent 
permeability coefficients obtained for granisetron and diclofenac transport through porcine skin were 
7.1 and 3.8 times higher for RF-treated skin compared to intact skin, respectively [100].  Experiments 
performed on rats in vivo with bioactive hGH showed a relative bioavailability of approx. 80% 
compared to subcutaneous injection [101]. 
A human safety study on twenty healthy, adult volunteers, reported slight erythema (0.75 out of 
8.0) and negligible pain (5 out of 100) as measured by the Draize irritation index and Visual Analogue 
Scale score, respectively.  An RF thermal ablation device has also been developed by Altea 
Therapeutics (PassPortÔ Patch; GA, USA) and is currently in Phase 1 human clinical trials in the U.S.  
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8. COMBINATION STRATEGIES 
An exhaustive inventory of all the possible combinations and implicated synergistic mechanisms 
with respect to transdermal enhancement offers subject matter for several articles and is clearly 
outside the scope of this review.  The reader is referred to a comprehensive summary of these 
combination strategies with respect to their efficacy and mechanisms [102].  Since the enhancement 
effect can be synergistic, this has added to the interest in the field.  Nearly all combinations have been 
tested, at least in vitro, and some of these have been applied to peptide drug delivery.  These include 
the combination of iontophoresis with chemical enhancers [103, 104], with electroporation [40, 105], 
and with jet injection pre-treatment [106].  The Medipad  (Elan Pharmaceutical Technologies, Ireland), 
is a hybrid system coupling iontophoretic delivery with shallow SC puncture [107].   
The use of two or more technologies – with different mechanisms of action – permits the same 
effect to be achieved with safer levels of the ‘active driving force’; for example, lower currents, or 
reduced levels of chemical enhancers.  However, paradoxically, this synergy may also result in an 
increased toxicity: consider the combination of chemical enhancers with iontophoresis or ultrasound.  
The use of an electrically-assisted method could increase the rate and extent of delivery of the 
chemical enhancer into the skin, or induce a deeper penetration into the tissues, with concomitantly 
increased skin irritation.  Hence, in addition to the evaluation of the practicality of certain dual 
technologies, which might lead to relatively complex devices, safety must be validated in vivo and in 
human volunteers before combination technologies can “take off” and be considered as realistic 
delivery platforms. 
9. NOVEL TECHNIQUES IN EARLY DEVELOPMENT 
The transdermal enhancement technologies presented below are relatively novel approaches in 
early development. Although they have yet to be validated with respect to peptide and protein delivery, 
they are included here because of their ability to overcome the SC barrier function to a greater extent 
than many conventional methods. 
9.1 Photomechanical Waves 
Photomechanical waves (PW) are broadband compressive waves generated by intense laser 
radiation [108].  A PW delivery device consists of a drug reservoir backed with a laser target material 
(e.g., polystyrene).  This system is placed on the skin and the laser is applied to the target.  The 
energy of the laser is strongly absorbed by the target, resulting in the formation of photomechanical 
waves which are hypothesised to transiently permeabilize the stratum corneum.  Drug diffuses 
passively through the channels momentarily created.  The mechanism of channel formation remains to 
be elucidated, but it is known that the effects of PW are due to mechanical forces [109]. 
Different molecules and even microspheres have been measured in the skin layers in vivo after 
PW application [110-113], yet, interestingly, this technique does not appear to permeabilize the 
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stratum corneum, in vitro.  An isolated report describes successful insulin delivery in rats in vivo (~80% 
decrease in blood glucose level), but after pretreatment with an anionic surfactant [114].  Clearly, this 
technique is still very much in its infancy and unlikely to be a realistic contender for transdermal 
peptide delivery.  
9.2 Heat-assisted drug delivery  
Controlled Heat-Assisted Drug Delivery (CHADD; Zars Inc., UT, USA) is the basis of an 
innovative patch consisting of a layer containing a heat-generating chemical component and a 
perforated cover membrane.  When the package is opened, air flows at a controlled rate through the 
holes in the cover membrane into the heating mixture and initiates a chemical reaction that 
spontaneously produces heat.  Heat generated within the patch increases skin temperature and 
thereby drug penetration rates across the skin.  According to the manufacturers, the temperature and 
duration of the reaction can be controlled by the size and number of holes in the cover membrane and 
the precise composition and quantity of the chemical components.  S-Caine PatchÔ (Zars Inc., UT, 
USA) is a new system for anæsthetic delivery [115], which uses the CHADD technology and which 
has successfully completed Phase III trials.  This technology has not yet been applied to peptide and 
proteins although systems containing a benzodiazepine and a 5-hydroxytryptamine receptor (5-HT3) 
antagonist are currently in preclinical development.  One obvious concern with respect to peptides and 
proteins is their thermal instability, which could severely limit the application of this technology. 
9.3 Microscissioning 
Microscissioning entails the use of sharp particles to scize defined areas of the skin.  
Techniques using a combination of momentum transfer and scizing are well known in cosmetic 
dermatology.  The relatively hard, roughened stratum corneum and epidermis resulting from aging 
processes can be removed by moderate velocity, sharp particles impinging obliquely against the skin 
surface.  However, only one published study reports the application of this technology to transdermal 
delivery.  Aluminium oxide particles (10 to 70 mm) were accelerated in a nitrogen stream under a 
pressure of 552 kPa, and directed towards the inner wrist of volunteers, after which the site was 
treated with lidocaine.  The experiments, performed on only two adult subjects, demonstrated full 
anaesthesia around the site within three minutes, whereas topical application without the microconduit 
required approximately 1.5 hours [116].  This technology is very experimental and requires 
considerable work, notably in terms of safety.  The presence of microparticulate debris in the skin as 
well as blood in the 200 mm diameter microconduit (although suggested to be useful for the purposes 
of clinical monitoring of analytes) points to the need for further investigation. 
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10. CONCLUSIONS 
The proliferation of research activity in the field of transdermal drug delivery serves to highlight 
the pressing need for alternatives to the conventional invasive administration of peptides and proteins 
via needles and syringes.  However, regardless of how attractive any new drug delivery concept may 
appear to be, it must not only deliver therapeutically realistic levels of drug to the target site, but must 
also prove its clinical superiority over conventional injections with respect to long-term safety, patient 
compliance, ease-of-use, impact on protein quality (physical, chemical and biological stability) and of 
course, commercial viability (high manufacturing costs would result in a non-viable product). 
It is perhaps this lack of clinical superiority over injectables, which prevents the velocity-based 
approach from being the technology of choice in transdermal peptide and protein drug delivery.  
Iontophoresis, which offers the unique advantage of tight control over the delivery kinetics, is expected 
to gain momentum now that devices are being commercialised.  However, one of the largest sub-
classes of the protein-based therapeutics developed by the biotechnology industry is that of 
monoclonal antibodies, which have been anticipated to represent 30% of pharmaceutical sales by 
2007 [83].  Given their size, iontophoresis, which is more suitable to peptide drugs, is certainly not the 
method of choice to deliver such large macromolecules.  Hence, there is an evident need for 
developing complementary technologies such as microneedles, which represent an excellent example 
of interdisciplinary research. 
With this large range of technologies currently under development, one can hope that in the not 
too distant future, there will be viable transdermal alternatives for the administration of protein and 
peptide based therapeutics thus reducing the need to resort to conventional injections. 
11. EXPERT OPINION 
The oral route is undoubtedly the preferred route of drug administration for most therapeutic 
agents and ideally, this would also be the case for peptide- and protein-based drugs.  However, the 
gastrointestinal tract has evolved to break down macromolecules, including polypeptides, and facilitate 
the absorption of their constituents.  Moreover, upon absorption, the hepatic portal vein takes these 
products to the liver, which is the primary site of biotransformation and conversion of these molecules 
and molecular fragments into products that can be easily eliminated.  Approaches such as 
microemulsions, covalent chemical modification, and carrier-mediated systems, have enabled the oral 
administration of macromolecules to move forward from the proof-of-concept stage.  However, unless 
a peptide (or protein) can be protected from, or rendered resistant to, the catabolic activity in the 
gastrointestinal tract, prohibitively large amounts of (expensive) therapeutic agent will have to be 
delivered to achieve the desired pharmacological effect.  One approach is to use peptides that contain 
D-amino acids and, in general, oral delivery may be more feasible for smaller peptides where there is 
no significant tertiary structure that must be retained.  Based on this logic, it is easier to explain the 
delivery of desmopressin by the oral route and the recent development of a tablet form for the 
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treatment of nocturnal enuresis.  However, with respect to the oral delivery of larger proteins with more 
complex structures, the likelihood of an oral formulation on the market place is far from the horizon.  
Some peptide drugs, for example, nafarelin, are currently available for administration via the 
nasal route.  However, the bioavailability of therapeutic peptides administered by this route is usually 
less than 5%, limiting its appeal and subsequent development.  Pulmonary delivery has aroused much 
interest and a great deal of effort has been devoted to developing pulmonary systems for the delivery 
of insulin.  The development of inhalation systems for targeted local drug delivery in the respiratory 
tract has progressed considerably with the availability of recombinant human deoxyribonuclease for 
the treatment of cystic fibrosis.  Such topical delivery is frequently to be preferred because systemic 
administration might not achieve the desired drug levels at the disease site, or because high systemic 
levels of the drugs, e.g., growth factors, that are required for a local effect at the target tissue, often 
cause unwanted systemic toxicity.  In addition to low bioavailability which, as with nasal delivery, can 
necessitate large and unacceptable drug doses, pulmonary delivery presents paradoxically another 
dilemma: the large alveolar surface area coupled with the extremely fine nature of the epithelium can 
result in an extremely rapid absorption with the risk of a large bolus effect.  Hence, it might be argued 
that the pulmonary delivery of proteins may be restricted to therapeutics that do not induce systemic 
side-effects at high peak serum concentrations or local tissue reactions at the site of absorption. 
The application of therapeutic agents to the skin was first realised for the treatment of 
dermatologic diseases.  Since a significant proportion of the population suffers from dermatological 
disorders, research in this field is expected to steadily continue.  Given some of the similarities in 
formulation strategies, transdermal delivery is expected to benefit from advances in localised dermal 
delivery.  However, the skin is a lipidic barrier membrane and as such, it does not lend itself to the 
facile delivery of hydrophilic or charged peptides and proteins.  Owing to the efficient barrier function 
of the skin, it is difficult to envisage the delivery of peptides with molecular weights greater than 5-10 
kDa at therapeutic input rates by truly non-invasive methods, such as iontophoresis or sonophoresis, 
which do not set out to puncture the membrane and introduce pores or similar transport channels.  It is 
certainly true that iontophoresis is well-suited to peptide delivery owing to the controlled input kinetics 
that it alone can provide.  For the transdermal delivery of larger macromolecules, we will have to resort 
to the “minimally-invasive” techniques such as microneedles and other related technologies that 
abrade or remove the stratum corneum.  These methods certainly open the door to the delivery of a 
much wider range of macromolecules.  The numerous jet-injectors also offer a different way into the 
body and are finding a useful niche for the non-invasive delivery of vaccines and this area, which is 
also open to exploitation by the microneedle platforms, may prove to be very fruitful.  These different 
delivery technologies provide complementary techniques for the administration of different types of 
peptides and proteins and there are clearly many opportunities and unmet needs to be addressed.  
For all of these platforms, the key to success will always be careful selection of the peptide/protein 
therapeutic agent. Given the advantages of the transdermal route, one can hope that the rational 
design and synthesis of therapeutics optimised for transdermal delivery with the correct mix of 
physicochemical properties is not too far off.  It is certain that only such close collaboration between 
medicinal chemists and formulation scientists will enable the successful delivery of tomorrow’s drugs. 
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Résumé 
L’objectif de cette étude était d’évaluer l’effet de la séquence en acides aminés sur 
l’administration transdermique des peptides par ionophorèse.  Une série de tripeptides cationiques de 
structure similaire basée sur les séquences (i) 6-8 de la LHRH (Ac-X-Leu-Arg-NH2) et (ii) 3-5 de 
l’octréotide (Ac-X-DTrp-Lys-NH2) ont été étudiés.  L’effet de la concentration en peptide sur le flux 
ionophorétique a été évalué par des expériences de transport réalisées in vitro sur de la peau de porc.  
L’administration simultanée de paracetamol a permis de séparer les contributions de l’électromigration 
(EM) et de l’électroosmose (EO) ainsi que de calculer un facteur d’inhibition électroosmotique (IF).  
Une augmentation de la concentration en peptide dans le compartiment donneur d’un facteur de 2 
induit une augmentation du flux ionophorétique de la plupart des peptides ainsi qu’une inhibition de 
l’électroosmose pour les peptides contenant DNal.  L’amélioration du transport ainsi que l’impact sur 
les composantes EM et EO étaient spécifiques aux peptides.  La réduction du nombre de ions 
compétiteurs dans la formulation augmenta le transport de façon importante, plus spécifiquement la 
contribution EM; elle augmenta également l’IF des composés susceptibles d’interagir avec la 
membrane.  Le flux se montra indépendant du poids moléculaire ainsi que du ClogP.  Le transport 
ionophorétique des peptides n’a pu être rationalisé en termes ni de poids moléculaire, ni de lipophilie 
estimée par méthode fragmentale.  Les résultats suggèrent qu’une approche tridimensionnelle plus 
complexe est nécessaire à l’établissement de relations structure-permeation gouvernant 
l’administration des peptides par ionophorèse. 
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Abstract  
The objective of this study was to investigate the effect of amino acid sequence on the 
transdermal delivery of peptides by iontophoresis.  Structurally-related, cationic tripeptides based on 
the residues at positions (i) 6-8 in LHRH (Ac-X-Leu-Arg-NH2) and (ii) 3-5 in octreotide (Ac-X-DTrp-Lys-
NH2) were studied.  Iontophoretic transport experiments were conducted using porcine skin in vitro to 
investigate the dependence of flux on peptide concentration.  Co-iontophoresis of acetaminophen 
enabled deconvolution of the contributions of electromigration (EM) and electroosmosis (EO) and the 
calculation of an electroosmotic inhibition factor (IF).  A two-fold increase in donor peptide 
concentration increased iontophoretic flux for most peptides, and electroosmotic inhibition for DNal-
containing tripeptides.  The improvement in transport and the impact on the EM and EO components 
were peptide-specific.  A reduction in the number of competing ions in the formulation significantly 
increased transport and, specifically, the EM contribution; it also increased IF of compounds with a 
propensity to interact with the membrane.  No monotonic dependence of flux on either molecular 
weight or lipophilicity was observed.  Iontophoretic peptide transport could not be rationalized in terms 
of either peptide molecular weight or computational 2D estimates of lipophilicity. Data suggest that a 
more complex three-dimensional approach is required to develop structure permeation relationships 
governing iontophoretic peptide delivery. 
Key words: Iontophoresis, electroosmosis, electromigration, skin, peptides 
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INTRODUCTION 
Constant current iontophoresis provides an efficient, controlled method of transdermal drug 
administration since the amount delivered is directly proportional to the quantity of charge passed (i.e., 
the product of the current intensity and the duration of current application).  Modulation of current 
intensity (and profile) enables the drug input rate to be customized to the needs of each patient, or 
phase of treatment, and offers the possibility of noninvasive pulsatile delivery. 
Iontophoresis may be particularly suited to the controlled transdermal delivery of low molecular 
weight peptide therapeutics since these are frequently potent, charged and certain among them, e.g., 
the LHRH analogues, can elicit different pharmacological effects depending on the delivery kinetics 
[1]. 
Under physiological conditions, the skin is negatively charged and convective solvent flow in the 
direction of cation movement complements electromigration and allows the transport of neutral 
molecules.  Hence, the steady-state iontophoretic flux of a cationic peptide (Jpep) is the sum of the 
electromigratory (JEM) and electroosmotic (JEO) contributions (assuming a negligible passive diffusion), 
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where zpep and cpep are the concentration and valence, respectively, of the peptide; F is the 
Faraday constant, and υ the electroosmotic flow; tpep is the fraction of the total applied current density 
(I) carried across the skin by the peptide, its so-called transport number, which can be further defined 
in terms of the charge, concentration and mobility (u) of all ions (i = 1 to n) in the system:  
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The mobilities and concentrations refer to those in the membrane but, for simplicity, are 
frequently considered to be either linearly dependent on, or equal to, the values in solution depending 
on the assumed degree of aqueous character of the transport pathway.  From Equation 1, it is clear, 
given the proportional dependence of iontophoretic flux on both drug concentration and applied 
current that increasing either parameter should increase the flux.  However, the iontophoretic transport 
of certain LHRH analogues, for example, nafarelin [2] and leuprolide [3], has a distinctly nonlinear 
dependence on the peptide concentration in the donor compartment.  Indeed, in a study examining the 
iontophoretic delivery of leuprolide to humans in vivo, plasma concentrations decreased as the 
concentration of the peptide in the iontophoretic device was increased [4].  Analogous behaviour was 
also observed during the iontophoretic delivery of octreotide to rabbits in vivo; bioavailability increased 
with current intensity but decreased with increasing peptide concentration [5]. 
In contrast to nafarelin and leuprolide, LHRH behaves as predicted by theory even though it only 
differs from these analogues in the amino acid at position six (a glycine in LHRH; D-naphthylalanine in 
nafarelin; D-leucine in leuprolide).  Both analogues contain lipophilic residues that, together with the 
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leucine at position 7, create a bulky lipophilic moiety directly adjacent to a positively charged residue 
(Arg8).  It has been suggested that the iontophoretic transport pathway contains accessible lipophilic 
surfaces and anionic sites capable of interacting with lipophilic cations.  In general, these interactions 
could reduce the overall iontophoretic flux for two reasons: (i) the interaction hinders drug transport by 
reducing the electrical mobility of the molecule, and (ii) strong binding could neutralize the skin’s 
negative charge and decrease EO. 
Iontophoresis of a series of oligopeptides, and their effect on mannitol flux, indicated that both 
lipophilicity and a positive charge were required for EO inhibition to occur [6].  These results validated 
the hypothesis that the amino acids at positions 6-8 in LHRH and nafarelin were the key to their 
unique iontophoretic transport behaviour.  The inhibitory effect of the tripeptides was related to their 
proposed lipophilicities [6].  Since the -Phe3-DTrp4-Lys5- sequence in octreotide has the same 
(hydrophobe-hydrophobe-cation) motif identified for the anomalous behavior of leuprolide and 
nafarelin, the inverse dependence of plasma octreotide levels and the peptide dose might also be 
attributed to EO inhibition. 
To-date there has been no systematic and quantitative study of the incremental effect of 
molecular weight/lipophilicity on iontophoretic peptide transport.  The aim of the present work was to 
study the effect of amino acid sequence on the iontophoretic behavior of cationic peptides and to 
identify the role of physicochemical parameters in controlling peptide electrotransport across the skin.  
The first series of structurally-related oligopeptides, Ac-X-Leu-Arg-NH2 (where X=Gly, DAla, DLeu, 
DSer, DCit, DPhe, DTrp, and DNal) was based on the amino acids found at positions 6-8 in LHRH 
analogues.  Substitution of the N-terminal residue enabled a systematic modification of the tripeptide’s 
physicochemical properties.  In addition to acetylation of the N-terminal and amidation of the C-
terminal, the presence of D-amino acids at the N-terminal position further improved resistance to 
cutaneous metabolism.  A second series of tripeptides was based on the sequence at positions 3-5 in 
octreotide (Ac-X-DTrp-Lys-NH2 (where X = Phe, Ser, and Tyr)).  Finally, a series of “hybrid” tripeptides 
(Ac-Phe-DTrp-Arg-NH2, Ac-DNal-Arg-Leu-NH2, Ac-Leu-DNal-Arg-NH2, and Ac-DNal-Leu-Lys-NH2) 
containing residues from the “LHRH” and “octreotide” series was also studied.  In addition to 
quantifying peptide transport, the iontophoretic flux of a co-administered EO marker was measured to 
assess the magnitude of convective solvent flow and to determine the relative contributions of each 
transport mechanism.  Prediction of the relative importance of EM and EO and the identification of 
molecular properties determining whether, and to what extent, a therapeutic peptide inhibits its own 
transport is clearly important for formulation design. 
MATERIALS AND METHODS 
Chemicals 
Tripeptides of the form Ac-X-Leu-Arg-NH2 (where X=Gly, Ala, DAla, DLeu, DSer, DPhe, DTrp, 
DCit (citrulline), and DNal (2-naphthylalanine), Ac-X-DTrp-Lys-NH2 (where X=Phe, Ser, and Tyr), Ac-
Phe-DTrp-Arg-NH2, Ac-DNal-Arg-Leu-NH2, Ac-Leu-DNal-Arg-NH2, and Ac-DNal-Leu-Lys-NH2 were 
Chapitre 2  39 
 
 
synthesized either by the Institute of Biochemistry at the University of Lausanne (Lausanne, 
Switzerland), or by NeoMPS Inc. (Strasbourg, France).  For conciseness, single letter codes have 
been used for the amino acids in the figures.  Acetaminophen and ninhydrin were purchased from 
Fluka (Sigma-Aldrich Chimie Sarl, France).  Tris (Tris-(hydroxymethyl) aminomethane), TrizmaÒ 
hydrochloride and agarose were obtained from Sigma-Aldrich (Sigma-Aldrich Chimie Sarl, France) 
and 1-heptanesulfonic acid sodium salt from Fisher Chemicals (Fisher Scientific, NJ). De-ionized 
water (resistivity > 18 Mohm/cm2) was used to prepare all solutions. 
Analytical procedures 
Arginine-containing tripeptides were quantified by high-performance liquid chromatography with 
on-line post-column fluorescence derivatization [7].  Briefly, the method involved detection of the 
fluorophore derived from condensation of the guanidine moiety of arginine with ninhydrin (contained in 
the mobile phase) in an alkaline stream.  The chromatographic system comprised a Model 600E 
solvent delivery pump, an in-line degasser, a Model 717plus injector and a reaction system equipped 
with a mixing tee, a single-piston pulse-dampened pump and a RXNÔ 1000 reaction coil (Waters 
Corporation, MA).  The mobile phase consisted of either 22 or 38% acetonitrile depending on the 
lipophilicity of the peptide.  The aqueous phase contained 15 mM sodium heptanesulfonate and 5 mM 
ninhydrin, adjusted to pH 3.5 with acetic acid.  The flow rate was 1 ml/min.  After elution through a 
Zorbax SB-C8 column (4.6 mm i.d., 25 cm long, 5 mm particle size) (Agilent Technologies Inc., CA), 
the stream was mixed with a 0.5 M sodium hydroxide solution delivered at a flow rate of 0.5 ml/min.  
Both the column and the reaction coil were maintained at 60°C.  A Waters 474 scanning fluorescence 
detector was used to detect the derivatized fluorophore using an excitation wavelength of 395 nm and 
an emission wavelength of 500 nm. 
The remaining peptides were quantified by high-performance liquid chromatography using the 
same column maintained at the same temperature, but with UV detection.  The mobile phase 
contained acetonitrile and a triethylaminephosphate buffer solution, pH 2.3.  The ratio of organic to 
aqueous phase was dependent on the compound: 30:70 for Ac-DNal-Leu-Lys-NH2 (detected at 228 
nm), 20:80 for Ac-Phe-DTrp-Lys-NH2, and 12:88 for Ac-Ser-DTrp-Lys-NH2 and Ac-Tyr-DTrp-Lys-NH2.  
These latter tripeptides were detected at 278 nm. 
The RSD of repeatability was less than 1% and the quantification limit was typically between 0.2 
and 0.4 mM for all the peptides assayed. 
Similarly, acetaminophen was assayed with a mobile phase comprising 92% water and 8% 
acetonitrile adjusted to pH 3.5 with acetic acid.  The flow rate was 1.5 ml/min.  Acetaminophen was 
detected by its UV absorbance at 243 nm.  The RSD of the repeatability was less than 1 % and the 
quantification limit was 0.7 mM. 
Skin preparation 
Porcine ears were obtained shortly after sacrifice from the local abattoir (SODEXA, Annecy, 
France) and were cleaned under cold running water.  The whole skin was removed carefully from the 
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outer region of the ear and separated from the underlying cartilage with a scalpel.  The tissue was 
then dermatomed (800 mm), wrapped in Parafilmä and maintained at –20°C before use for a period no 
longer than 2 months. 
Iontophoresis procedure 
The skin was clamped in three-compartment vertical flow-through diffusion cells (area: 0.726 
cm2), the design of which has been previously described [8].  Tripeptides (2.18 or 4.36 mM) were 
dissolved in a 154 mM Tris/TrizmaÒ HCl-buffered solution (pH 7.4).  In addition to the peptide, the 
donor solution (1 ml) always contained 15 mM acetaminophen, which was used to report on the 
convective solvent flow.  The cathodal compartment was filled with 1 ml of 25 mM Tris/TrizmaÒ HCl-
buffered (pH 7.4) normal saline.  The receptor compartment, containing ~6 ml of the same electrolyte 
solution, was magnetically stirred and perfused at a flow rate of ~3 ml/h.  
In a second series of experiments, the anode was isolated from the donor solution via a salt 
bridge (100 mM Tris/Trizma HCl in 3% agarose) to minimize the effect of competing ions.  In this case, 
the anodal compartment contained a solution of 25 mM Tris/TrizmaÒ HCl normal saline buffered to pH 
7.4.  The solutions in the donor compartment comprised 4.36 mM of the respective peptide and 15 
mM acetaminophen dissolved in 20 mM Tris/TrizmaÒ HCl (pH 7.4).  
In all experiments, a constant current (0.5 mA/cm2) was applied for 8 hours via Ag/AgCl 
electrodes connected to a power supply (KepcoÒ, NJ). 
All measurements were made in at least triplicate, using skin from different pigs. 
Quantifying EO inhibition 
Acetaminophen is a neutral hydrophilic compound, with poor passive permeability, that can be 
iontophoretically driven through the skin by electroosmosis.  It was therefore included in the peptide 
formulation in the donor compartment (15 mM) as a marker for the direction and magnitude of 
convective flow. 
For each experiment, an Inhibition Factor (IF) was calculated using the following equation:  
IF = [QA-8h,control] / [QA-8h,peptide] (3) 
where QA-8h,control is the amount of acetaminophen transported into the receptor phase during 8 hours 
of iontophoresis in the absence of peptide, and QA-8h,peptide is the corresponding quantity when a 
tripeptide was simultaneously iontophoresed. 
Determination of EM and EO contributions to iontophoresis 
The iontophoretic flux (J) of a charged species is the sum of the component fluxes - JEM and JEO – 
due to electromigration and electroosmosis (assuming that the passive permeability is negligible): 
pepEOpepEM JJJ ,, +=  (4) 
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During iontophoresis, the current-induced flow of water (Vw) across the skin can be estimated 
from [9]: 
aceacew CJV /=  (5) 
where Jace is the acetaminophen flux and Cace is its concentration in the donor compartment.  It follows 
that, if Vw has been quantified in the presence of drug, then the convective component of its 
iontophoretic transport (JEO) can be calculated by multiplying Vw by the peptide concentration in the 
donor solution (Cpep) [10]: 
pepwEO CVJ ×=  (6) 
This analysis makes three assumptions: (a) that peptide and acetaminophen are transported in 
a similar fashion by convective solvent flow, (b) that transport of peptide and acetaminophen is 
independent and there is no interaction between the two species, and (c) that EO transport of the 
marker molecule is proportional to its concentration in the solvent.  
It follows that equations (4)-(6) can be used to estimate the relative contributions of EO and EM 
to the total iontophoretic flux of the peptide. 
Transport number determination 
Transport number was calculated for each tripeptide according to the following equation (derived from 
Equation 1): 
TI
Ftransportpeptidecumulativet peptide ×
×
=  (7) 
where F is the Faraday constant (96485 C/mol), I is the applied current intensity and T the duration of 
current application. 
Peptide accumulation in the skin 
The uptake of peptide by the skin during iontophoresis was also quantified.  Once the current 
was stopped, the dermatomed skin sample was washed with water, dried on absorbent paper, and 
then placed in 4 ml of the mobile phase used in the HPLC analytical method to extract the peptide.  
After stirring for 14 hours, the solution was filtered (0.45 mm regenerated cellulose syringe filter, 
Alltech, IL) and the peptide was quantified in the normal way. 
Data treatment 
The results were derived from at least triplicate experiments conducted with skin samples 
originating from different pig ears.  Outliers, determined using the Grubbs test, were discarded.  When 
two sets of data where compared, Student t tests were performed.  The level of statistical significance 
was fixed at P < 0.05. 
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RESULTS AND DISCUSSION 
Effect of peptide concentration 
The impact of doubling the donor concentration from 2.18 to 4.36 mM was tested for each 
tripeptide.  The iontophoretic flux for each peptide at the two concentrations is presented graphically in 
Figure 1.   
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Figure 1. The influence of donor [peptide] and [Tris+] on peptide transport across porcine skin in vitro. 
The data for each named peptide is shown in the upper panel (a); the spread of data is illustrated in the lower 
graph (b).  SB denotes the use of a salt bridge to decrease electrolyte concentration. 
According to Faraday’s Law, at low concentrations, and in the absence of peptide-membrane or 
peptide-peptide interactions, electrotransport should increase proportionally with concentration in the 
presence of background electrolyte [11].  However, while doubling the donor concentration resulted in 
significantly increased fluxes for nearly all tripeptides, fluxes of Ac-DNal-Leu-Arg-NH2 and Ac-Leu-
DNal-Arg-NH2 at 4.36 mM were not statistically different from those measured from a donor 
concentration of 2.18 mM.  This can be partly explained by the suppression of convective solvent flow 
induced by these peptides.  Effectively, these two peptides, which both possess a bulky lipophilic 
moiety (leucine adjacent to 2-naphthylalanine) were the only molecules to exhibit EO inhibition 
(IF=2.2; Figure 2).  These results are consistent with the previously reported observation that although 
DNal-Leu-Arg had a significant effect on electroosmosis, there was no inhibition during iontophoresis 
of Ala-Leu-Arg [6]. 
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Figure 2. The influence of donor [peptide] and [Tris+] on electroosmotic inhibition.  
IF =  [QA-8h,control] / [QA-8h,peptide] (see Equation 3 for definitions). 
The data for each named peptide is shown in the upper panel (a); the spread of data is illustrated in the lower 
graph (b). 
SB denotes the use of a salt bridge to decrease electrolyte concentration. 
 
Next, we wished to address whether the transport efficacy of the peptides investigated could be 
correlated to one or several aspects of their physical chemistry (e.g., molecular weight and 
lipophilicity).  However, despite the expansive range of peptides tested - encompassing a spectrum of 
physicochemical signatures, their iontophoretic transport remained, surprisingly, unaffected.  This is 
illustrated in Figure 1, where the mean Jss for each peptide has been plotted as a function of the donor 
formulation; while peptide fluxes generally increased at the higher donor concentration, they did not 
appear to be peptide-specific.  Similarly, their impact on EO at the higher peptide concentration was 
only discernible for two of the peptides tested (Figure 2).  That is, the data dispersion was not 
sufficient to enable discrimination between the peptides on the basis of their physical chemistry. 
Since phenomena such as peptide aggregation and EO inhibition, which are dictated by amino 
acid sequence, and which ultimately affect total iontophoretic transport, are generally concentration-
dependent, it is possible that the use of higher concentrations would have allowed discrimination 
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between the peptides.  However, due to the limited amounts of peptide available, an alternative 
approach was employed to increase transport efficacy.   
Effect of competing ions on peptide delivery 
Ag/AgCl electrodes need chloride ions for anodal electrochemistry (~100mM – for the 
experiments described here) derived from either the molecule under study or from an external source 
(e.g., NaCl or buffer); in the latter case the number of competing cations in the anodal formulation is 
greatly increased.  To increase peptide transport efficacy, the number of competitive cations in the 
donor compartment can be reduced (~20 mM) by using a salt bridge assembly.  This is illustrated in 
Figure 1, which shows the doubling of iontophoretic fluxes upon decreasing donor [Tris+] 
approximately 5-fold.  This increased transport efficacy was similarly reflected by the calculated 
transport numbers: experiments performed at 4.36 mM without a salt bridge resulted in transport 
numbers ranging from 0.0004 to 0.003; values as high as 0.0086 were obtained with the reduced 
levels of donor Tris+.  As a consequence, the EM contribution to the total iontophoretic peptide flux 
was increased when the number of competitive charge carriers was decreased. 
In addition to increasing peptide transport, the reduced competition from donor cations also 
resulted in a more pronounced inhibition of EO for the majority of peptides (Figure 2).  For compounds 
with a propensity to interact with the membrane, the entry of greater quantities of peptide into the skin, 
leads to greater skin charge neutralization and hence, reduced convective solvent flow. 
The total iontophoretic flux is the linear combination of the EM and EO contributions (Eq. (1)).  
Assuming that these components are independent, it is possible to examine the effect of increasing 
peptide concentration on each component separately.  First, with respect to EM, if the peptide 
concentration in the donor compartment is increased from cpep,1 to cpep,2 (assuming that the 
proportionality constant between the concentrations in solution and skin is unity), then the ratio of the 
EM fluxes, JEM,2/JEM,1, is given by: 
( )
( )
21,
12,
1,
2,
å
å=
iiipep
iiipep
EM
EM
cuzc
cuzc
J
J
  (9) 
where (Sziuici)n refers to the sum of products of the valence, mobility and concentration of the 
competing charge carriers for the two formulations, respectively.  Under the experimental conditions 
used in this study, the donor compartment contained protonated Tris in addition to the peptide, and the 
receiver contained Cl- ions, therefore expansion of Equation 9 yields: 
( )
( )2,1,
1,2,
1,
2,
peppepClClTRISTRISpep
peppepClClTRISTRISpep
EM
EM
cucucuc
cucucuc
J
J
++
++
=  (10) 
Two limiting conditions are easily identified: 
Case 1: [electrolyte] >> [peptide] 
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Case 2: [peptide] >> [electrolyte] 
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EM
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peppepClClTRISTRISpeppep J
J
cucucucu  (12) 
Thus, at low peptide concentrations, the ratio of EM fluxes is equal to the ratio of the 
concentrations (Case 1).  As peptide concentration is increased relative to the electrolyte levels, the 
EM flux ultimately becomes independent of concentration and the ratio tends to unity (Case 2).  Since 
the background electrolytes in the donor and receiver compartments were in significant excess (either 
20 or 154 mM Tris cation in the donor and 154 mM chloride anion in the receiver) compared to the 
peptide (2.18 or 4.36 mM), CASE 1 was considered to hold for these experiments. 
The effect of increasing peptide concentration on EO can be expressed as follows:  
1,
2,
1,
2,
1,
2,
pep
pep
pep
pep
EO
EO
c
c
vc
vc
J
J
==  (13) 
Based on Equations 11 and 13, a two-fold increase in peptide concentration is expected to 
result in a corresponding increase in the EM and EO contributions.  The ratio of EM (JEM(4.36/2.18)) 
and EO (JEO(4.36/2.18)) contributions at the two peptide concentrations are shown in  Figure 3a.  The 
JEM(4.36/2.18) and JEO(4.36/2.18) ratios for the Ac-X-DTrp-Lys-NH2 tripeptides were clustered around 
the predicted value of 2, suggesting an equivalent effect on both transport mechanisms.  However, 
there was more variability associated with the Ac-X-Leu-Arg-NH2 series. 
Upon subsequent reduction of the donor electrolyte concentration, the EM and EO contributions 
were markedly different (Figure 3b).  Under these conditions the relative contribution of EO was 
significantly reduced as evidenced by JEO(4.36+SB/2.18) < 1 for most peptides.  In contrast, 
JEM(4.36+SB/2.18) was much higher, ranging from 1 to 8.  The reduced EO was manifested by those 
peptides displaying an IF greater than 1 (Figure 2a).  Concomitantly, the reduction in the number of 
competing cations, significantly increased the fraction of current transported by the tripeptides, 
accounting for an EM contribution of 77 to 93% to the overall transport. 
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Figure 3.  The effect of donor peptide concentration (a) and the subsequent impact of reduced donor 
electrolyte (Tris+) levels (b) on the contributions of EM and EO to iontophoretic transport.   
(A) The y-axis, Ji(4.36/2.18), represents the flux ratio of either EM or EO at the two peptide concentrations (2.18 
and 4.36 mM). 
(B) The y-axis, Ji(4.36+SB/2.18), expresses the additional influence of reduced donor Tris+ levels. 
The anomalous behaviour of the Ac-X-Leu-Arg-NH2 series is further illustrated by Figure 4, 
which compares the transport behaviour of Ac-Gly-Leu-Arg-NH2 and Ac-DNal-Leu-Arg-NH2 under 
various experimental conditions.  Whereas the flux of the former was dependent on donor peptide and 
electrolyte levels, transport of the latter was indifferent to the experimental conditions employed 
(Figure 4). 
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Figure 4.  Iontophoretic fluxes and inhibition factors of Ac-Gly-Leu-Arg-NH2 and Ac-DNal-Leu-Arg-NH2 as 
a function of the experimental conditions.  
A = Donor peptide conc. 2.18 mM and electrolyte conc. 154 mM; B = Donor peptide conc. 4.36 mM and 
electrolyte conc. 154 mM and C = Donor peptide conc. 4.36 mM and electrolyte conc. @20 mM. 
Peptide accumulation in the skin does not always imply EO inhibition 
At the end of the iontophoretic experiments, bound peptide was extracted from the skin samples 
and quantified.  Generally, greater amounts were recovered for those peptides exhibiting the highest 
inhibition factors.  For example, in the absence of excess Na+, significantly more Ac-Leu-DNal-Arg-NH2 
(260 ± 30 mg, IF = 8 ± 5) was recovered than Ac-DCit-Leu-Arg-NH2, (47 ± 16 mg, IF = 1.1 ± 0.3).  
Conversely, however, the mere accumulation of a cationic peptide in the membrane was not in itself a 
sufficient condition for significant EO inhibition; as typified by Ac-Phe-DTrp-Lys-NH2, (330 ± 40 mg, IF = 
1.8 ± 0.4).  This peptide has approximately the same molecular weight as Ac-Leu-DNal-Arg-NH2; 
although similar amounts were retrieved from the respective skin samples, the latter is a significantly 
more powerful EO inhibitor, as evidenced by its IF, which is ~4.7-fold greater. 
Effect of peptide physicochemical properties on iontophoretic delivery  
Molecular weight and lipophilicity are among physicochemical parameters commonly used to 
describe variations in passive transport across biological membranes.  However, for these model 
tripeptides, there appeared to be no correlation between their transdermal iontophoretic transport and 
either molecular weight or calculated lipophilicity (Figure 5).   
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Figure 5.  Peptide fluxes as a function 
of a) Molecular weight and b) logP 
values calculated using Daylight 
ClogP (Daylight Chemical Information 
Systems, Inc., Mission Viejo, CA 
(www.daylight.com)).  
Donor peptide conc. 4.36 mM and 
electrolyte conc. @ 20 mM. 
 
For example, the flux of Ac-DNal-Leu-Arg-NH2 (MW = 526 Da), was ~10-fold lower than that of 
Ac-DTrp-Leu-Arg-NH2, a peptide of comparable molecular weight (MW = 515 Da).  More striking was 
the lack of correlation between peptide flux and lipophilicity over values of calculated P spanning 5 
orders of magnitude.  The flux of Ac-DNal-Leu-Arg-NH2 (ClogP = 0.26) was more than 5-fold lower 
than that of Ac-Phe-DTrp-Arg-NH2, a peptide only slightly less lipophilic (ClogP of -0.15).  This strongly 
suggests that 1D- and 2D-descriptors cannot adequately explain iontophoretic transport in terms of 
peptide physicochemical properties, and that a computational study involving the 3D-spatial 
distribution of these properties over the entire molecular surface is necessary to explain the observed 
transport kinetics. 
CONCLUSIONS 
The electrically-assisted delivery of structurally related tripeptides derived from the amino acid 
sequences at positions 6-8 in LHRH (Ac-X-Leu-Arg-NH2) and 3-5 in octreotide (Ac-X-DTrp-Lys-NH2) 
was investigated to identify the effect of single amino acid substitutions on iontophoretic transport.  
Co-iontophoresis of acetaminophen enabled deconvolution of the EM and EO contributions.  Although 
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increasing donor peptide concentration generally produced an increase in peptide flux, the relative 
effects on EM and EO were peptide-dependent.  Transport was further increased when electrolyte 
levels were reduced and under these conditions, the dominance of electromigration was more 
pronounced.  Nevertheless, certain tripeptides, where the first two residues created a large 
hydrophobic surface in proximity to the positive charge at the C-terminal position were able to shut 
down convective solvent flow.  Qualitatively, lipophilic cations appeared to have poorer transport; 
however there was no direct dependence of transport on either molecular weight or calculated log P.  
It is possible that peptide flux depends on the spatial distribution of lipophilicity and other 
physicochemical parameters.  The increased data dispersion obtained with reduced levels of donor 
electrolyte should prove useful for ongoing computational studies aimed at identifying (i) structure-
permeation relationships governing peptide iontophoresis and (ii) the impact of specific 
physicochemical properties and their spatial distribution on delivery. 
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Résumé 
Cette étude a pour objectifs (i) d’évaluer l’importance de la séquence en acides amines, (ii) 
d’étudier comment la distribution spatiale des propriétés physicochimiques des peptides influence leur 
électrotransport, (iii) de développer un modèle quantitatif permettant de prédire le passage des 
peptides.  Les résultats expérimentaux ont montré que la séquence en acides aminés, qui détermine 
la distribution des propriétés moléculaires au sein du peptide, exerce un effet important sur 
l’administration par ionophorèse : différents arrangements des même résidus résultent en des 
transports différents.  Des études computationnelles ont permis de générer des relations structure-
perméation quantitatives tridimensionnelles (3D-QSPR) basées sur des descripteurs 3D.  Le modèle 
prédit que la ionophorèse est favorisée par l’hydrophilie des peptides alors qu’elle est entravée par 
une hydrophobie volumineuse et localisée.  Les caractéristiques moléculaires qui favorisent 
l’électrotransport à travers la peau sont contraires à celles requises pour une diffusion passive.  Les 
résultats présentent la première analyse de l’électrotransport de peptides en termes de distribution 
spatiale des propriétés moléculaires et offrent un premier pas vers la prédiction ab initio de 
l’administration transdermique des peptides par ionophorèse 
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Abstract 
The aims of this study were (i) to evaluate the importance of amino acid sequence, (ii) to 
investigate how the spatial distribution of peptide physicochemical properties influence their 
electrotransport, and (iii) to develop a quantitative model with which to predict peptide transport rates.  
Experimental results showed that amino acid sequence, which determines the distribution of molecular 
properties over the peptide surface, significantly affected iontophoretic delivery: different 
arrangements of the same residues resulted in different transport behavior.  Computational studies 
generated three-dimensional Quantitative-Structure-Permeation-Relationships (3D-QSPR) based on 
3D descriptors.  The model predicted that iontophoresis was favored by peptide hydrophilicity but 
hindered by voluminous, localized hydrophobicity.  The molecular characteristics that favor 
electrotransport are the converse of those required for passive diffusion across the skin. The data 
represent the first analysis of peptide electrotransport in terms of the spatial distribution of molecular 
properties and provide insight into the ab initio prediction of transdermal iontophoretic peptide delivery.   
Keywords:  transdermal iontophoresis; electroosmosis; skin; peptide; QSPR 
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The skin represents an easily accessible, relatively large site for drug administration.  However, 
the barrier properties of the skin restrict the number of systemically-acting drugs that can be passively 
delivered by this route to a select group of low molecular weight, potent compounds with the 
appropriate balance of physicochemical properties.  Transdermal delivery of potent, therapeutic 
peptides is precluded by their polar (or charged) nature, which limits their transport across the stratum 
corneum, the lipidic rate-limiting barrier to percutaneous transit.  Moreover, attainment of delivery rates 
required to achieve and to maintain therapeutic levels, by simple passive diffusion, would probably 
require large (and unrealistic) patch areas as well as the use of aggressive chemical enhancers to 
reduce skin barrier function (an approach that is likely to be unacceptable for chronic application 
because of local irritation). 
Iontophoresis is an electrically-assisted drug delivery technology that enables non-invasive, 
controlled administration of low molecular weight peptide therapeutics.  A small electric potential is 
used to drive ions into the body; increased drug mobility enables greater amounts to be delivered in 
shorter times.  Drug input rate is controlled by the applied current intensity enabling individualized 
therapy according to patient needs and disease progression.  Moreover, modulation of the current 
allows complex drug delivery profiles to be achieved.  For example, continuous delivery of the LHRH 
analog, leuprolide, used in the treatment of prostate cancer, suppressed testosterone levels and 
resulted in biochemical castration in human volunteers [1].  In contrast, pulsatile administration of 
LHRH, again in humans, was able to mimic the body’s natural release profile and promoted secretion 
of LH [2].  
Electrotransport occurs through two principal mechanisms: electromigration (direct effect of the 
applied electric field on the charged species) and electroosmosis (convective solvent flow in the 
anode-to-cathode direction, as a result of the skin’s net negative charge at physiological pH).  
Although theory suggests, and experiments typically confirm, that electrotransport generally increases 
proportionally with current density and concentration [3], the transport of certain cationic compounds, 
including several peptides, shows the opposite behavior, a phenomenon attributed to an inhibition of 
electroosmosis [4-7].  Subsequent studies, involving measurement of mannitol flux, a marker for 
electroosmosis, during the iontophoresis of a series of oligopeptides, suggested that the presence of a 
bulky hydrophobic moiety adjacent to a positively charged residue, enabled the peptides to bind to the 
negatively charged skin membrane, thereby eliminating the membrane’s cationic permselectivity, and 
shutting down electroosmosis [8]. 
To-date there has been no systematic, quantitative study into the key molecular properties that 
govern peptide electrotransport.  The objectives of the present investigation were to identify these 
parameters and to demonstrate that 1- and 2-dimensional descriptors are inadequate measures to 
account for the complex behavior observed: even for small, dynamic oligopeptides, transport can only 
be interpreted accurately in terms of the 3-dimensional spatial distribution of these properties over the 
molecular surface.  Thus, different arrangements of the same amino acids within a given peptide 
significantly alter transport behavior.  The longer-term goal was to use experimentally determined 
iontophoretic tripeptide fluxes to develop a quantitative structure-permeation relationship (QSPR) 
capable of ab initio prediction of electrotransport.  While several models have been proposed to 
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predict passive skin permeation [9], none employing molecular properties (beyond molecular weight) 
have been developed to explain “active” delivery by iontophoresis. 
RESULTS 
Molecular weight and 2-dimensional parameters are inadequate descriptors of peptide 
transport 
Because of their greater mobilities in an electric field, low molecular weight cations display much 
higher iontophoretic permeabilities than high molecular weight proteins; but molecular weight or size is 
not a sufficiently discriminating parameter to explain subtle differences in transport.   
 
Figure 1. Absence of correlation 
between iontophoretic peptide flux 
and either (a) molecular weight 
(Daltons), or (b) calculated octanol-
water partition coefficient (ClogP).  
Open circles correspond to lysine-
containing peptides 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1a clearly shows that this parameter cannot explain the differences observed between 
the peptides studied here.  For example, Ac-DTrp-Leu-Arg-NH2 (n°11) and Ac-DNal-Leu-Arg-NH2 (n°1) 
have similar molecular weights (515 and 526 Da, respectively), but the flux of the former is ~12-fold 
greater (150 ± 50 versus 13 ± 6 nmol/cm2/h).  Similarly, since iontophoretic peptide transport [8] has 
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been correlated with lipophilicity, octanol-water partition coefficients (ClogP) were calculated for all 
compounds.  Although it is generally preferable to use log D to denote lipophilicity of ionizable 
compounds, log P was used here as the ionization state of all the peptides studied was assumed to be 
identical since the experimental pH was always 3 units below the pKa of the basic residue.  Thus the 
effect of ionization on lipophilicity was assumed to be constant in this homologous series of tripeptides 
originated from either arginine or lysine residue.  Figure 1b shows that ClogP is poorly correlated with 
measured peptide flux.  For instance, Ac-Phe-DTrp-Lys-NH2, which is only slightly more hydrophilic 
than Ac-DNal-Leu-Arg-NH2 (calculated ClogP values of 0.263 and 0.449, respectively), had a 10-fold 
higher flux (130 ± 30 versus 13 ± 6 nmol/cm2/h).  Furthermore, multilinear regression analysis failed to 
establish a satisfactory correlation between peptide flux and conventional two-dimensional (2D) 
parameters (e.g., solvent accessible surface area, molecular flexibility, topological indices) included in 
the DRAGON software package [10] (data not shown).  This suggested that 2D descriptors were 
poorly adapted to the task of interpreting electrotransport of these peptides across the skin.  In light of 
these results, a three-dimensional approach was adopted. 
Quantifying physicochemical properties over the 3D molecular surface  
An iterative variable selection allowed a large decrease of the VolSurf molecular descriptors 
derived from the WATER probe, the DRY probe, MLP and MHBPs.  Indeed starting from the 148 
original parameters, only the 24 most pertinent descriptors were retained to describe the iontophoretic 
flux and led to a two-component PLS model, which accounted for 85% of the total variance of the 
matrix (Figure 2).   
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Figure 2.  Relationship between experimental and calculated peptide iontophoretic fluxes using 
the two-component PLS model (13 compounds, 24 descriptors, r2 = 0.85, q2 = 0.78). 
 
The coefficient plot of this model (Figure 3a) shows the contribution of the retained 24 VolSurf 
descriptors.  The vertical bars represent the contribution of each individual descriptor, the height of the 
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columns reflecting the weight of the contribution.  Positive coefficients correspond to descriptors that 
favor peptide transport.   
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Figure 3. PLS coefficient plots correlating VolSurf descriptors with (a) peptide iontophoretic 
flux, and (b) electroosmosis inhibition.   
Volume (V) = isoenergetic contours of hydrophobic interaction regions; capacity factors (CF) = volume 
parameters (Vhydrophilic or Vhydrophobic), divided by the total molecular surface; integy moments (I) = 
resultant (or sum) of the vectors pointing from the centre of mass of the molecule to the centres of the 
hydrophobic regions. 
 
According to this plot, a good iontophoretic transport is favored by molecular hydrophilicity, as 
indicated by the positive Capacity factors derived from the WATER probe (CFWater).  In contrast, the 
descriptors of hydrophobic interactions (VMLPphob, IMLPphob and CFMLPphob) are inversely correlated with 
the measured transdermal fluxes, demonstrating the negative effect of hydrophobicity on peptide 
iontophoretic delivery.  The strongly negative contributions of the integy moments (IMLPphob, resultant 
(or sum) of the vectors pointing from the centre of mass of the molecule to the centres of the 
hydrophobic regions) reveal a major influence of the hydrophobicity distribution on transport; localized 
hydrophobicity, asymmetrically distributed over the molecular surface creates potential interaction 
sites with the membrane that may impede transport. 
As in the case of the peptide flux, an iterative variable selection procedure allowed the 
identification of the most relevant VolSurf descriptors encoding for properties describing 
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electroosmosis inhibition.  Although less successful, the model was nevertheless able to establish a 
correlation between IF and these molecular descriptors.  The coefficient plot (Figure 3b) shows that 
electroosmotic inhibition, and hence decreased transport, is induced by strong hydrophobic 
interactions (positive VMLPphob and CFMLPphob), confirming the above findings that these properties 
hinder peptide transport (Figure 3a).  Moreover, the spatial distribution of the physicochemical 
properties over the molecular surface was again shown to play a role.  Neutralization of skin charge 
and concomitant abolition of electroosmosis was favored by localized hydrophilicity, as evidenced by 
the magnitude of the hydrophilic integy moment contribution (positive IWater).  In physical terms, 
localized hydrophilicity (corresponding to positive charge centers) creates a site capable of strong 
electrostatic interaction with the fixed negative charges in the skin. 
Predicting iontophoretic peptide transport  
The experimental data showed that significantly different fluxes were observed for two 
tripeptides containing different arrangements of the same amino acids, specifically Ac-DNal-Leu-Arg-
NH2 (13 ± 6 nmol/cm2/h) and Ac-Leu-DNal-Arg-NH2 (32 ± 11 nmol/cm2/h).  The PLS model was also 
sensitive to the amino acid arrangement (Figure 2).  The predictive power of the model was, therefore, 
tested by delivering an additional peptide, Ac-Leu-Gly-Arg-NH2, comprising the same amino acids as 
Ac-Gly-Leu-Arg-NH2 - a member of the original (training) set - but with the amino acids arranged in a 
different order.  The predicted iontophoretic flux of Ac-Leu-Gly-Arg-NH2 (149 ± 10 nmol/cm2/h) was 
significantly higher than that of Ac-Gly-Leu-Arg-NH2 (93 ± 1 nmol/cm2/h; calculated). This result was in 
very good agreement with experiments since the iontophoretic flux of Ac-Leu-Gly-Arg-NH2 (150 ± 30 
nmol/cm2/h) was measured higher than that of Ac-Gly-Leu-Arg-NH2 (92 ± 14; experimental). 
DISCUSSION 
Passive diffusion versus iontophoretic delivery 
Accurate in silico prediction of skin permeability to drug substances and other chemical agents 
present in the environment would have considerable utility for both transdermal drug delivery and 
toxicology fields.  This has led to the development of several mathematical models that attempt to 
relate passive skin permeability to the penetrant’s physicochemical properties [9].  Many of these 
models have identified lipophilicity as a key property, which positively contributes to skin permeation 
[11-14].  A recent study using the same 3D molecular interaction fields as used here related the 
physicochemical properties of 79 compounds to their passive permeation across human epidermis in 
vitro (Bajot F., Geinoz S., Rey S., Cruciani G., Guy R. H., Carrupt P.-A., The Volsurf approach in 
structure-permeation relationships: molecular interaction fields focused on specific intermolecular 
interactions, manuscript in preparation).  It was found that good passive skin permeation was favored 
by bulky, localized hydrophobic regions, and that large hydrophilic interaction volumes were 
unfavorable.  In the present study, we have demonstrated that transdermal peptide iontophoresis is 
favored by increased hydrophilicity (as measured by the hydrophilic capacity factor, CFWater) but 
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hindered by strong, localized hydrophobic interactions.  These results emphasize the differences 
between passive and electrically-assisted transport across the skin, and corroborate the idea that 
different transport mechanisms and pathways are involved in passive and electrically-assisted 
transport.  Whereas passive solute permeation occurs mainly via the intercellular, lipidic matrix of the 
stratum corneum [15], it seems likely that ionic shunts [16], essentially aqueous pathways, are 
predominantly involved in iontophoresis. 
External prediction of flux 
Although additional peptides must be tested to determine the real predictive power of the model, 
the similarity between the predicted and experimental iontophoretic flux of Ac-Leu-Gly-Arg-NH2 
constitutes a promising first step towards the validation of the predictive capacity of the model. 
Impact of amino acid sequence 
The experimental iontophoretic flux of Ac-Leu-Gly-Arg-NH2 (150 ± 30 nmol/cm2/h) and Ac-Gly-
Leu-Arg-NH2 (92 ± 14 nmol/cm2/h) confirmed that amino acid sequence influences peptide transport.  
In addition to higher hydrophilic capacity factors, Ac-Leu-Gly-Arg-NH2 has significantly smaller and 
less localized hydrophobic regions thereby (according to the PLS model) favoring iontophoretic 
peptide transport.  Figure 4 illustrates the bulkier hydrophobic surfaces in Ac-Gly-Leu-Arg-NH2 
compared to Ac-Leu-Gly-Arg-NH2.   
 
 
Figure 4. Hydrophobic interactions calculated using the MLP field for (a) Ac-Gly-Leu-Arg-NH2, and (b) Ac-
Leu-Gly-Arg-NH2 at 0.34 kcal/mol.  Integy moments (resultant (or sum) of the vectors pointing from the centre of 
mass of the molecule to the centres of the hydrophobic regions) are shown as grey bars.  
The favored 3D configuration of Ac-Leu-Gly-Arg-NH2 places the leucine side chain adjacent to 
arginine, reducing the “apparent hydrophobicity” of the former and hindering its participation in 
hydrophobic interactions.  Moreover, the carbonyl group in the peptide bond between the Leu and Arg 
residues, provides a polar interaction site, further reducing the lipophilicity of leucine.  It can be seen 
that the hydrophobic interaction region in Ac-Gly-Leu-Arg-NH2 is both larger and more localized and 
accessible.  According to the model, therefore, this localization will influence interactions with the skin 
) 
b) a) 
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transport pathways, and have an impact on the overall transdermal flux.  This effect of amino acid 
arrangement on transdermal iontophoretic delivery is worth further investigation. 
Impact of charge type 
Peptides derived from the somatostatin analogues (Ac-X-DTrp-Lys-NH2), with a C-terminal 
lysine residue, exhibited significantly higher fluxes than their counterparts derived from LHRH (Ac-X-
Leu-Arg-NH2) in which the positive charge originates from the C-terminal arginine residue.  To 
determine whether charge type was implicated in this difference, “hybrid” peptides were synthesized in 
which the arginine in Ac-DNal-Leu-Arg-NH2 (from nafarelin) was replaced by lysine, and the lysine in 
Ac-Phe-DTrp-Lys-NH2 (from octreotide) was replaced by arginine.  Figure 5a shows that, whereas the 
replacement of arginine by lysine increased the “nafarelin-type” peptide flux from 13 ± 6 to 40 ± 12 
nmol/cm2/h, the reverse transformation decreased the “octreotide-type” peptide flux from 130 ± 30 to 
80 ± 17 nmol/cm2/h.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Comparing arginine and lysine 
positive charges.   
(a) Effect of charge type on the anodal 
iontophoretic flux of four cationic peptides.  
(b) Electrostatic potential distributions on 
the Van der Waals molecular surface of Ac-
Phe-DTrp-Arg-NH2 (left) and Ac-Phe-DTrp-
Lys-NH2 (right), calculated using the SYBYL 
6.9 molecular modelling package (Tripos 
Associates, MO).  Increasing charge density 
is colour-coded from blue to red. 
 
Charge type certainly appeared to play a significant role, therefore, in the iontophoretic transport 
of cationic oligopeptides - with the primary amine in the lysine side-chain functioning as a more 
favorable positive charge centre than the more delocalized guanidinium group present in arginine.  
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Visualization of the spatial distribution of the electrostatic potential, around the respective charge 
centres on the Van der Waals molecular surface, confirmed the more localized charge, and greater 
charge density, for the primary amine group in lysine (Figure 5b). 
CONCLUSIONS 
The current study provides the first systematic, quantitative analysis of iontophoretic peptide transport.  
It was shown that conventional 2D descriptors could not be correlated to the measured fluxes and that 
it was essential to consider the 3D environment, in particular, the spatial distribution of molecular 
descriptors.  A PLS model was developed and demonstrated that increasing hydrophilicity favored 
peptide transport, whereas bulky and localized hydrophobic regions were a hindrance.  Comparison 
with the preferred physicochemical characteristics for passive diffusion emphasized that iontophoretic 
and passive diffusional transport pathways must be different.  Moreover, the arrangement of the 
constituent amino acids, even for dynamic tripeptide systems, governs electrotransport.  This finding 
merits further investigation as the development of iontophoretic drug delivery systems, especially 
those incorporating peptides, is pursued. 
METHODS 
Log P calculation.  Log P values were calculated using Daylight ClogP version 4.73 (Daylight 
Chemical Information Systems, Inc., Mission Viejo, CA (www.daylight.com)) 
Overview of the 3D approach. The procedure consisted of the following major steps: 
1. Modelling 3D peptide molecular structures. 
2. Computation of the Molecular Lipophilicity Potential (MLP), Molecular hydrogen-bonding 
potentials (MHBPs ) and GRID 3D molecular fields. 
3. Generation of the VolSurf descriptors. 
4. Statistical analysis using partial least squares discriminant analysis (PLS). 
Dataset.  Iontophoretic fluxes of 13 tripeptides derived from LHRH and somatostatin analogs were 
measured in vitro across porcine ear skin, using vertical diffusion cells with a salt bridge system (full 
experimental conditions and a complete description of the effect of formulation conditions on peptide 
transport are given in Y.B.S., A.N., R.H.G. and Y.N.K., Effect of amino acid sequence on transdermal 
iontophoretic peptide delivery, submitted to European Journal of Pharmaceutical Sciences).  All 
tripeptides were blocked both at the N-terminal (by acetylation) and the C-terminal (by amidation) so 
that the charge was only provided by the constitutive amino acid side chains.  For conciseness, single 
letter codes have been used for amino acids in the graphics.  (Cit = Citrulline and Nal = 2-
Naphthylalanine).  Acetaminophen, a neutral hydrophilic compound with poor passive permeability, 
that can be driven through the skin only by electroosmosis, was incorporated in the donor 
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compartment as a marker of the magnitude of convective flow.  For each peptide, an Inhibition Factor 
(IF) was calculated according to the following equation:  
IF = [QA-8h,control] / [QA-8h,peptide] (1) 
where QA-8h,control is the amount of acetaminophen transported into the receptor phase during 8 hours 
of iontophoresis when no peptide was present in the donor solution, and QA-8h,peptide is the 
corresponding quantity when the tripeptide was iontophoresed simultaneously. 
Permeation and inhibition data are collated in Figure 6. 
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Figure 6. Fluxes and inhibition factors of peptides iontophoresed across porcine ear skin in vitro. 
Modelling of 3D molecular structures.  Tripeptides were drawn in their charged state using the 
biopolymer building tool of Sybyl 6.9 (Tripos Associates, MO, 1995), and energy-optimized using the 
Tripos force field (Tripos Associates, MO, 1995).  For each tripeptide, a conformational search was 
performed using the Sybyl Genetic Algorithm protocol.  The lowest energy structure was retained and 
optimized using the Tripos force field.  Minimizations were performed in vacuo (e = 1). 
Computation of 3D molecular fields (GRID, MLP and MHBPs).  The GRID field is one of the most 
widely used computational tools to map molecular surfaces of drugs and macromolecules [17].  It uses 
a potential based on the total energy of interaction (the sum of Lennard-Jones, H-bonding and 
electrostatic terms) between a target molecule and a probe, which can either be a single atom or a 
group of atoms.  By moving probes over the surface of the target molecule, GRID yields a property 
distribution of attractive and repulsive forces between the probe and the target molecule.  The 
molecular interaction fields were calculated using the WATER and the DRY probes available in the 
GRID program [18].  The WATER probe simulates hydrophilic interactions, whereas the DRY probe 
encodes for polarizability.   
At a given point in space, the MLP represents the result of the intermolecular interactions encoded by 
the lipophilicity of all fragments in the molecule [19].  Thus, the MLP represents the relative affinity of a 
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solute for water and octanol.  The MLP spreads out molecular lipophilicity on the solvent-accessible-
surface of a molecule, allowing a quantitative visualization by color coding.  Negative MLP values 
correspond to “hydrophilic” parts of the molecule, whereas positive MLP values (MLPphob) quantify 
pure hydrophobic interactions.  Molecular hydrogen-bonding potentials (MHBPs) allow the exploration 
of three-dimensional H-bonding properties.  The development of this tool is based on a stepwise 
procedure comparable to that used to calculate the MLP.  Two MHBPs are generated, able to 
distinguish between donor (MHBPdo) and acceptor (MHBPac) H-bonding properties [20]. 
Generation of VolSurf descriptors.  VolSurf allows the extraction of one-dimensional numerical 
descriptors from 3D-isoenergetic (isopotential) contours [17].  The most important descriptors, 
calculated at different energy levels, are: 
· Volumes (V), corresponding to the space enclosed by the isoenergetic contours of hydrophilic 
(hydrophobic) interaction regions 
· Integy moments (I), which are resultants (or sums) of the vectors pointing from the centre of 
mass of the molecule to the centres of the hydrophilic (hydrophobic) regions 
· Capacity factors (CF), which are the volume parameters (V), divided by the total molecular 
surface 
Statistical analysis.  PLS analysis was performed with SIMCA-P 6.1 (Umetrics AB, Sweden, 1996) 
using default settings.  A “leave-one-out” cross-validation procedure was used to quantify the 
predictive power of the PLS model, yielding the predictive correlation coefficient (q2) [21,22].  
Descriptors were discarded if their associated coefficient possessed a confidence interval (derived 
from jack knifing) larger than the coefficient itself.  An iterative procedure was used to progressively 
refine the model and retain the most relevant descriptors. 
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4 Debiopharm, Galenic Unit, CH-1196 Gland, Switzerland 
Résumé 
But.  Evaluer la faisabilité de l’administration transdermique du vapréotide, analogue de la 
somatostatine, par ionophorèse. 
Méthode.  Des expériences in vitro ont été réalisées avec de la peau d’oreille de porc soit 
dermatomisée, soit traitée à la chaleur pour l’obtention de l’épiderme.  En plus de la quantification du 
transport du vapréotide dans et à travers le tissu cutané, l’effet de l’administration du peptide sur la 
permsélectivité de la peau a également été mesuré.  L’influence (i) de la densité de courant appliqué 
(ii) du traitement de la peau avant et après ionophorèse, (iii) des ions compétiteurs et (iv) de l’inclusion 
d’albumine dans le récepteur sur l’administration du vapréotide ont été étudiés. 
Résultats.  L’épiderme s’est révélé être un meilleur modèle que la peau dermatomisée pour l’étude 
du transport du vapréotide.  Malgré sa susceptibilité à la dégradation enzymatique, un flux de 1.7 
mg/cm2/h a pu être atteint après 7 heures d’ionophorèse à courant constant (0.15mA/cm2).  
L’extraction après ionophorèse a révélé qu’en fonction des conditions expérimentales, 80 à 300 mg de 
peptide étaient fixés dans la peau.  Le vapreotide interagit avec la peau et exerce une inhibition de 
l’électroosmose dépendante du courant.  Cependant, ni les stratégies de pré-traitement pour saturer 
les sites de fixation, ni les protocoles suivis après ionophorèse dans le but de déplacer le peptide lié 
se sont avérés efficaces. 
Conclusions.  Sur la base du flux de vapréotide mesuré et de ses propriétés pharmacocinétiques, il 
apparaît que des concentrations thérapeutiques sont atteignables avec un patch de 15 cm2. 
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Abstract 
Purpose.  To evaluate the feasibility of delivering vapreotide, a somatostatin analogue, by 
transdermal iontophoresis. 
Methods.  In vitro experiments were conducted using dermatomed porcine ear skin and heat-
separated epidermis.  In addition to quantifying vapreotide transport into and across the skin, the 
effect of peptide delivery on skin permselectivity was also measured.  The influence of (i) current 
density, (ii) pre- and post-treatment of the skin, (iii) competitive ions, and (iv) inclusion of albumin in 
the receptor on vapreotide delivery were investigated.   
Results. Epidermis proved to be a better model than dermatomed skin for vapreotide transport 
studies.  Despite the susceptibility of vapreotide to enzymatic degradation, a flux of 1.7 mg/cm2/h was 
achieved after 7 hours of constant current iontophoresis (0.15 mA/cm2).  Post-iontophoretic extraction 
revealed that, depending on the experimental conditions, 80-300 mg of peptide were bound to the skin.  
Vapreotide was found to interact with the skin and displayed a current-dependent inhibition of 
electroosmosis.  However, neither the pre-treatment strategies to saturate the putative binding sites, 
nor the post-treatment protocols to displace the bound peptide were effective. 
Conclusion.  Based on the observed transport rate of vapreotide and its known pharmacokinetics, 
therapeutic concentrations should be achievable using a 15 cm2 patch. 
Keywords:  transdermal iontophoresis; vapreotide; electroosmosis; skin barrier 
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INTRODUCTION 
Vapreotide is one of several potent long-acting analogues of somatostatin synthesized for 
clinical use in the treatment of acromegaly and endocrine tumors of the gastroenteropancreatic 
system.  It has additionally demonstrated success in the early treatment of oesophageal variceal 
bleeding and has been awarded orphan drug status in the US [1].  These analogues require 
subcutaneous or intramuscular administration.  In an attempt to avoid the parenteral route, more 
convenient “patient-friendly” routes of drug delivery have been investigated.  The results have been 
mixed: orally administered octreotide (an other somatostatin analogue commercialized as 
Sandostatin®) is hampered by a relatively low bioavailability [2] and because of poor local tolerability, 
nasal administration is also inconvenient [3].  The transdermal route is an attractive alternative to 
deliver therapeutic drugs [4].  The physicochemical properties of peptides (charged; high molecular 
weight) render them inappropriate for passive transdermal delivery.  In contrast, iontophoresis, an 
electrically-assisted drug delivery technology, offers a controlled and non-invasive means of 
administration [5].  The two main transport mechanisms during iontophoresis are electromigration 
(direct effect of the applied electric field on the charged species) and electroosmosis (convective 
solvent flow in the anode-to-cathode direction, as a consequence of the skin’s net negative charge at 
physiological pH).  Since electrical mobility decreases with molecular weight, it is hypothesised that 
electroosmosis is the major transport mechanism for peptides [6].  However, it is also known that 
peptides containing adjacent cationic and lipophilic residues can inhibit electroosmosis, and their own 
transport, by altering skin permselectivity [7-12].  The association of these lipophilic cations with the 
membrane neutralizes, to varying extents, the intrinsic negative charge of the skin causing a 
significant reduction in the normal anode-to-cathode electroosmotic flow.  Since the degree of 
inhibition depends on the number of molecules in the skin, it is usually more pronounced at higher 
applied current densities and at increased peptide concentrations. 
The iontophoretic delivery of octreotide has been successfully achieved in rabbits in vivo [13].  
An investigation of the effect of current density and drug concentration on plasma levels of octreotide 
revealed a decrease in the amount of peptide delivered, with increasing concentration.  This might be 
attributed to an inhibition of electroosmosis, since the -Phe3-D-Trp4-Lys5- sequence in octreotide 
corresponds to the structural moiety thought to be a pre-requisite for this phenomenon [10]. 
The aim of the current study was to evaluate the feasibility of delivering vapreotide by 
transdermal iontophoresis.  In view of the structural similarity of vapreotide to octreotide, the 
iontophoretic delivery of vapreotide was expected to interact with the skin and affect electroosmotic 
solvent flow.  Hence, in addition to quantifying peptide transport, the magnitude of electroosmotic flow 
was also determined under the different experimental conditions employed.  Experiments were also 
conducted in the presence of a salt bridge; this allowed the use of lower electrolyte concentrations in 
the donor compartment, decreasing the number of competing charge carriers and, in theory, 
increasing peptide delivery efficiency (5).  The impact of current density and salt bridge use on both 
peptide transport and electroosmotic inhibition was measured.  Different approaches to modulate the 
interactions between the peptide and the skin were investigated, including co-iontophoresis with 
cetrimide, pre- and post-iontophoretic treatment of the skin with Ca2+ and propranolol - substances 
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capable of interacting with the biomembrane and occupying potential “peptide” binding sites.  
Vapreotide transport across heat-separated epidermis and dermatomed skin was compared. 
MATERIALS AND METHODS 
Chemicals 
Vapreotide (MW = 1131.4) D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2, in the form of its 
acetate salt was a generous gift from Debiopharm (Debiopharm Galenic Unit, Switzerland).  
Acetaminophen was purchased from Fluka (Sigma-Aldrich Chimie Sarl, France).  Tris (Tris-
(hydroxymethyl) aminomethane), TrizmaÒ hydrochloride, agarose, DL-propranolol and cetrimide were 
obtained from Sigma-Aldrich (Sigma-Aldrich Chimie Sarl, France) and bovine serum albumin was 
purchased from Fluka BioChemika (Sigma-Aldrich Chimie Sarl, France).  De-ionized water (resistivity 
> 18 MOhm/cm2) was used to prepare all solutions. 
Analytical procedures 
Vapreotide extracted from skin samples was quantified using a high-performance liquid 
chromatography system equipped with a variable wavelength UV detector (Waters Corporation, MA, 
USA).  The mobile phase, comprising 25% acetonitrile and 75% triethylaminephosphate buffer 
solution (pH = 2.3), was passed through a C18 PartiSphere column (4.6 mm i.d., 12.5 cm long, 5 mm 
particle size) (Whatman Inc., NJ, USA) maintained at 40°C, at a flow rate of 1 mL/min. The peptide 
was detected at 280 nm.  The RSD of the repeatability was less than 1 % and the limit of quantification 
was 115 ng/ml.  Direct competitive enzyme immunoassay (EIA), as a result of its superior sensitivity, 
was used to quantify the presence of vapreotide in the receptor compartment.  This competitive 
binding assay is based on the relative affinity of (i) the vapreotide (in the sample) and (ii) an enzymatic 
tracer prepared by covalent coupling of vapreotide to an enzyme (acetylcholinesterase), to anti-
vapreotide antibodies.  The quantification limit corresponded to 100 pg/ml. 
Acetaminophen was assayed by high-performance liquid chromatography using a Hypersil 
BDS C8 column (150 mm x 4.6 mm, SupelcoÒ, France) maintained at 40°C.  The mobile phase 
(delivered at a flow rate of 1 mL/min) consisted of 92% water and 8% acetonitrile adjusted to pH 3.5 
with acetic acid.  Acetaminophen was detected by its UV-absorbance at 243 nm.  The RSD of the 
repeatability was less than 1 % and the quantification limit was 22 ng/ml. 
Skin preparation 
Porcine ears, obtained from a local abbatoir (Société d’Exploitation d’Abbatage, Annecy, 
France) within a few hours post-mortem, were cleaned under cold running water.  The whole skin was 
removed carefully from the outer region of the ear and separated from the underlying cartilage with a 
scalpel.  The tissue was then either dermatomed (800 mm) or heat-treated to separate the epidermis 
[14]: pieces of fresh full-thickness skin were immersed in water at 58°C for 2 minutes after which the 
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epidermis was carefully separated from the dermis with a spatula.  Pieces of epidermis and 
dermatomed skin were wrapped individually in Parafilmä and maintained at –20°C until use and were 
stored for no longer than a period of 2 months. 
Iontophoresis procedure 
The skin was clamped in three-compartment vertical diffusion cells (area: 0.73 cm2), the 
design of which has been previously described [15].  Unless otherwise stated, vapreotide was 
dissolved in a 100 mM NaCl solution that was adjusted to pH = 5.5 with HCl to produce a 3 mM 
solution of the peptide; 1 mL of this solution was placed in the donor (anodal) compartment.  In 
addition to vapreotide, the donor compartment always contained 15 mM acetaminophen.  The 
cathodal compartment was filled with 1 mL of 25 mM Tris/TrizmaÒ HCl-buffered (pH 7.4) normal 
saline.  The receptor compartment (~6 mL) was filled with the same electrolyte solution, containing in 
addition, when stated, 44 g/L bovine serum albumin (BSA; to mimic physiological conditions) and was 
stirred magnetically throughout the permeation experiments.  
Constant current iontophoresis was used throughout the study. The current, ranging from 0.05 to 0.5 
mA/cm2 was applied for 4 to 24 hours via Ag/AgCl electrodes connected to a power supply (Kepco, 
NJ, USA). When specified, the anode was isolated from the donor solution via a salt bridge (100 mM 
Tris/Trizma HCl in 3% agarose) to minimize the competition between the peptide and the electrolytes 
necessary for the anodal reaction.  Under these conditions, the anodal compartment contained a 
solution of 25 mM Tris/TrizmaÒ HCl normal saline buffered to pH 7.4 and the vapreotide in the donor 
compartment was dissolved in 20mM Tris/TrizmaÒ HCl  (pH 7.4).  Schematic representations of these 
two different experimental set-ups are provided in Figure 1. 
 
Figure 1. Schematic representations of the iontophoretic diffusion cell assemblies used in this study. 
Quantifying electroosmotic inhibition 
Acetaminophen is a neutral hydrophilic compound, with poor passive permeability (~2 
nmol/cm2/h); under the influence of an electrical current, this uncharged but polar molecule is driven 
through the skin predominantly by electroosmosis.  Hence, in these studies it was incorporated into 
the donor formulation (15 mM) to report on convective solvent flow. 
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For each experiment, an Inhibition Factor (IF) was calculated using the following equation:  
IF = [QA-8h,control] / [QA-8h,peptide] (1) 
where QA-8h,control is the amount of acetaminophen transported into the receptor phase during 8 hours 
of iontophoresis when no peptide was present in the donor solution, and QA-8h,peptide is the 
corresponding quantity when vapreotide was iontophoresed. 
Effect of current density 
To evaluate the effect of current density on electroosmotic inhibition by vapreotide, current 
densities of 0.15, 0.3 and 0.5 mA/cm2 were applied for 8 hours across dermatomed skin.  A solution of 
3 mM vapreotide in 20 mM Tris/TrizmaÒ HCl buffered to pH 7.4 was placed in the donor compartment. 
Additional experiments were also performed using heat-separated epidermis to assess the 
effect of current density on the amount of vapreotide transported.  Again, a 3mM vapreotide donor 
solution was iontophoresed for 8 hours. 
Vapreotide accumulation in the skin 
The uptake of vapreotide into dermatomed skin during iontophoresis was also investigated.  
Upon terminating current application, the skin sample was rinsed with water, dried on absorbent 
paper, and then placed in 4 mL of a mixture acetonitrile/water (25/75).  After agitation for 14 hours, the 
solution was filtered (0.45 mm regenerated cellulose syringe filter, Alltech, IL, USA) and the amount of 
peptide quantified. 
Skin metabolism experiments 
The influence of porcine ear skin on the stability of vapreotide was evaluated by filling the 
receptor compartment with a 5 mM vapreotide solution in 25 mM Tris/TrizmaÒ HCl-buffered (pH 7.4) 
normal saline.  Both dermatomed and epidermal skin samples were separately evaluated.  The anodal 
and cathodal compartments were filled with 1 mL of 25 mM Tris/TrizmaÒ HCl-buffered (pH 7.4) normal 
saline.  A current of 0.15 mA/cm2 was applied for eight hours and the percentage of intact peptide was 
calculated as follows: 
Intact peptide (%) = %100x
peptideofamountInitial
peptideofamountFinal
 (2) 
Modifying interactions between vapreotide and the skin 
Co-iontophoresis: 1 mL of 4.4 mM vapreotide in 20 mM Tris/TrizmaÒ HCl (pH 7.4) containing either 
0.1% or 1%  (2.7 or 27 mM) cetrimide was placed in the anodal compartment and a current of 0.15 
mA/cm2 was applied for either 8 or 24 hours. 
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Pre-treatment: Vapreotide iontophoresis was preceded by the iontophoretic delivery of either 
propranolol or cetrimide: 
A:  A solution of 40 mM propranolol or 0.1% cetrimide in 25 mM Tris/TrizmaÒ HCl (pH 7.4) normal 
saline was placed in the anodal compartment and a current of 0.3 mA/cm2 was applied for 8 
hours. 
B:  Subsequently, 1 mL of 4.4 mM vapreotide in 20 mM Tris/TrizmaÒ HCl (pH 7.4) was placed in the 
donor compartment and a current of 0.15 mA/cm2 was applied for 24 hours using a salt-bridge. 
Post-treatment: Solutions of CaCl2, NaCl, propranolol and cetrimide were tested with respect to their 
capacity to release vapreotide bound to, and accumulated within, dermatomed skin.  These 
experiments also comprised two parts: 
A:  1 mL of vapreotide (3 mM) in 20 mM Tris/TrizmaÒ HCl (pH 7.4) was placed in the donor 
compartment and a current of 0.15 mA/cm2 was applied for 24 hours using a salt-bridge. 
B:  Solutions of either 100 mM CaCl2, 100 mM NaCl, 40 mM propranolol or 0.1% cetrimide in 25 mM 
Tris/TrizmaÒ HCl (pH 7.4) normal saline were added to the anodal compartment and a current of 
0.3 mA/cm2 was applied for 8 hours. 
For each pre- and post-treatment experiment, the receptor compartment was replaced between phase 
A and phase B. 
Data treatment 
The results were derived from at least triplicate experiments conducted with skin samples 
originating from different pig ears.  Outliers, determined using the Grubbs test, were discarded.  When 
two sets of data where compared, Student t tests were performed.  The level of statistical significance 
was fixed at P < 0.05. 
RESULTS AND DISCUSSION 
Skin metabolism of vapreotide 
Cutaneous metabolism has been widely investigated [16-18] and several studies into 
transdermal peptide delivery have reported the presence of proteolytic activity in the skin [9;19-21].  
With the concentration tested, only 39 ± 18% of the vapreotide in contact with the dermal face of 
dermatomed skin samples was found to be intact after 8 hours of iontophoresis.  Similarly, only 32 ± 
5% of the peptide remained intact after exposure to the interior epidermal surface.  The levels of 
degradation observed following exposure to either dermatomed skin or isolated epidermis were not 
significantly different.  
Although the presence of proteolytic enzymes in the skin is generally accepted, their exact 
location and distribution in the distinct tissue layers of the skin remains unknown.  Although the 
epidermis is claimed to be the major site of drug degradation, activity has also been ascribed to the 
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dermis [17].  Skin contact studies with vapreotide suggest that both epidermal and dermal tissues 
possess some form of proteolytic activity.  Moreover, the results also demonstrate that the enzymes 
located in the epidermis are resistant to the heat separation treatment used to isolate the epidermal 
membrane. 
Nevertheless, it is difficult to extrapolate these in vitro results to the eventual situation in vivo 
(particularly in humans), notably due to major interspecies differences in the structure and function of 
such enzymes.  In addition, the residence time of the peptide in the enzymatic barrier is likely to be 
significantly reduced in vivo as molecules reaching the epidermal-dermal junction are taken up rapidly 
by the skin’s microcirculation.  Although enzymatic activity is expected to be higher in viable tissues, it 
can be argued that ex vivo skin preparation procedures might result in increased release of 
intracellular enzymes.  However, the skin tissue used in these permeation experiments was frozen 
prior to use, a process reported to reduce metabolic activity of skin samples [22].  Thus, in vitro/in vivo 
correlations for labile peptides are complicated by the interplay of these opposing factors. 
Vapreotide transport 
Under the same iontophoretic conditions, significantly more (~10-fold) vapreotide was 
transported across the epidermis (~10 mg) than across dermatomed skin (~1 mg) when using the 
experimental set-up employing a salt-bridge (Figure 2).   
Figure 2. Cumulative amount of vapreotide 
measured in the receptor compartment after 8 
hours of iontophoresis at 0.15 mA/cm2 across 
epidermis and dermatomed skin as a function 
of the experimental set-up. (A: With Salt bridge, 
B: Without salt bridge, C: Without salt bridge; with 
BSA).  
There were statistically significant differences 
between epidermis and dermatomed skin in each 
corresponding experimental condition (p < 0.05). 
It is generally accepted that the remarkable barrier function of the skin is primarily located in the 
outermost layer of the epidermis, the stratum corneum, and that, in vivo, substances are taken up by 
the capillary network adjacent to the epidermal-dermal junction, after diffusing on the order of 100 mm 
through the membrane.  In separate studies (data not shown), there was no difference between the 
amount of vapreotide transported across tape-stripped and intact dermatomed skin, suggesting that 
the stratum corneum was not the rate-limiting barrier to transport at least under in vitro conditions.  
The use of dermatomed skin (~800 mm in thickness) in these in vitro experiments introduces an 
additional mass of dermal tissue, which acts as a “pseudo-receptor” compartment, notably for 
compounds such as vapreotide, which display a high skin affinity.  Therefore, the presence of dermis 
provides an artifactual reservoir for the drug that has already crossed the epidermis, and which, in 
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vivo, would be taken up by the capillaries just below the epidermal-dermal junction.  Thus, epidermis, 
which is a well-established model for transdermal drug delivery, appears to be more appropriate than 
dermatomed skin for transdermal vapreotide transport studies.  The fate of a peptide reservoir in vivo, 
if indeed it exists, remains to be studied. 
Vapreotide accumulation in the skin 
Despite the inefficient transfer of vapreotide across dermatomed skin, significant amounts of 
the peptide (80-300 mg) were recovered from the skin samples after iontophoresis (Table I).  These 
peptide accumulation data further attest to the suspected strong association between molecules 
possessing a positive charge, in close proximity to a lipophilic surface, and the skin.  In addition to 
these specific interactions between the peptide and structures present in the skin, the accumulation 
may also be the result of peptide-peptide interactions, which result in vapreotide aggregation and 
eventually in peptide deposition in the transport pathways.  
Table I. Vapreotide accumulation in the skin after iontophoretic current application for 8-24h using 
formulations containing 1.5-4.4 mM vapreotide.  Experiments were conducted using the experimental 
set-up shown in Figure 1b. 
Experimental condition 
Amount of vapreotide  
in the skin [mg] 
24h iontophoresis at 0.15 mA/cm2, 
4.4 mM donor concentration 
210 ± 10 
8h iontophoresis at 0.15 mA/cm2, 
3 mM donor concentration 
80 ± 20 
18h iontophoresis at 0.5 mA/cm2, 
1.5 mM donor concentration 
300 ± 60 
 
Effect of vapreotide transport on skin permselectivity  
Previous studies investigating iontophoretic transport across hairless mouse, rabbit, porcine 
and human skin have confirmed the existence of skin permselectivity, a phenomenon which gives rise 
to electroosmosis and contributes to the iontophoretic transport of neutral and cationic species [23-25].  
Moreover, the ability of certain lipophilic, peptidic and non-peptidic cations to inhibit the convective 
solvent flow has also been established [10;11;26].  The magnitude and significance of this inhibition 
depends on the skin type and the physicochemical properties of the molecule.  The effect of current 
density on the inhibition of electroosmosis by vapreotide is illustrated in Figure 3.  The inhibitory 
capacity of vapreotide is strongly dependent on the applied current density, increasing the inhibition 
factor by almost 50-fold at 0.5 mA/cm2.  As current density is increased, more charge has to be 
transported across the skin; this is partly carried by the peptide, which is driven into the membrane in 
greater amounts, leading to a more extensive neutralization of the skin’s negative charge and a more 
pronounced inhibition of electroosmosis. 
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Figure 3. Cumulative amounts of 
acetaminophen delivered across porcine ear 
skin during 8 hours of transdermal 
iontophoresis at 0.05, 0.15, and 0.5 mA/cm2 in 
the presence and absence of vapreotide.  The 
inhibition factor is calculated according to 
Equation 1. 
 
Effect of reducing competing ions in the formulation  
Because Ag/AgCl electrodes need chloride ions for anodal electrochemistry, the anodal 
compartment must contain a supply of such ions derived from either the active agent (e.g., 
hydrochloride salts) or from an external source, e.g., NaCl, in which case the total number of cations in 
the anodal formulation is greatly increased.  These cations compete with the positively-charged drug 
as charge carriers.  The use of a salt bridge enables fewer competing cations (~20 mM) to be 
incorporated in the donor compartment, increasing vapreotide transport efficacy, as indicated in Figure 
2.  To confirm that the ionic strength and not the donor pH, which also varied between the two 
experimental set-ups, was responsible for the modified transport of vapreotide, the effect of pH was 
also investigated.  A control experiment using the ‘salt bridge’ set-up was performed at pH 5.5 and 
revealed that there was no significant difference in the quantity of vapreotide transported (11.9 ± 3.8 
mg/cm2 at pH 5.5 versus 10.7 ± 4.5 mg/cm2 at pH 7.4). 
Figure 4. The electroosmotic inhibition factor 
after 8 hours of iontophoresis at 0.15 mA/cm2 
across epidermis and dermatomed skin as a 
function of the experimental set-up. (A: With Salt 
bridge, B: Without salt bridge, C: Without salt bridge; 
with BSA). 
There were statistically significant differences 
between the IFs observed with and without salt 
bridges for both epidermal and dermatomed skin 
samples (p < 0.05). 
 
Figure 4 indicates that the inhibition factor is increased two-fold in the presence of the salt 
bridge.  As discussed above, vapreotide transport increases with use of a salt bridge; hence, more 
peptide reaches the skin membrane, resulting in a more complete neutralization of skin charge and, as 
a result, greater reduction in electroosmotic flow.  However, this increased inhibition is not sufficient to 
outweigh the increased transport resulting from the reduced ion competition (Figure 2).  Finally, the 
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degree of electroosmotic inhibition was also independent of the skin preparation and experimental 
conditions employed (Figure 4).  
In addition to increasing the proportion of charge carried by the peptide, salt bridges allow the 
isolation of the peptide from the electrode compartment and have the advantage of preventing 
interactions between the electrode and the drug.  Patch-based iontophoretic systems employing the 
same principles have been developed where the electrode is separated from the drug reservoir by a 
size exclusion membrane [27]. 
Modifying interactions between vapreotide and the skin  
Given the substantial amounts of peptide measured in the skin, the liberation and subsequent 
transport of even a small fraction of this bound peptide would result in the delivery of significant 
amounts of drug.  A number of different approaches, as shown in Figure 5, were employed to 
modulate the impact of peptide-skin interactions on vapreotide transport.   
Co-application
Pre-treatment
Vapreotide + Cetrimide 
co-iontophoresis
Propranolol
Iontophoresis
Cetrimide
Iontophoresis
Vapreotide Iontophoresis
Vapreotide Iontophoresis
Post-treatment
NaCl Iontophoresis
CaCl2 Iontophoresis
Propranolol Iontophoresis
Cetrimide Iontophoresis
Vapreotide 
Iontophoresis
PHASE A PHASE B
 
Figure 5.  Experimental strategies investigated to reduce the degree of vapreotide fixation to the skin. 
The first approach involved co-iontophoresis of the cationic surfactant, cetrimide.  The results in 
Figure 6a show that co-iontophoresis of 0.1% cetrimide led to a two-fold reduction in the amount of 
peptide recovered from the skin.  As shown in Figure 6b, increasing the cetrimide concentration from 
0.1% to 1% produced a greater effect.  Although it is tempting to attribute this to an interaction of the 
cationic cetrimide with putative binding sites, the observation that peptide transport through the 
membrane was not increased, suggests that the surfactant itself acted as a competing charge carrier. 
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Figure 6.  Effect of co-iontophoresis of cetrimide on the amount of vapreotide bound to the skin.  (a) Co-
iontophoresis of 0.1% surfactant with 4.4 mM vapreotide for 24 hours at 0.15 mA/cm2. (b) Co-iontophoresis of 0.1 
and 1% surfactant with 4.4 mM vapreotide for 8 hours at 0.15 mA/cm2. 
 
To exclude the risk of competition, subsequent studies employed pre-and post-treatment of 
the skin wherein cetrimide and other species known to bind to the membrane, e.g., Ca2+ and 
propranolol were iontophoresed either prior to or after vapreotide iontophoresis.  It has been proposed 
that the lower transport number of Ca2+ as compared to Na+ is due to its superior interaction with 
negatively-charged binding sites in the skin [28].  Likewise, the iontophoresis of propranolol (40 mM) 
has been shown to reduce the electroosmotic transport of mannitol across porcine ear skin [26].  Pre-
iontophoretic treatment with either cetrimide or propranolol was thus attempted to saturate the putative 
binding sites, and hence prevent the interaction of vapreotide with the skin.  Vapreotide transport 
following these pre-treatments was not statistically different from the control (p < 0.05).  Previous 
reports showed that cetrimide pretreatment reduced iontophoretic delivery of propranolol and this was 
attributed to a neutralisation of skin charge (29).  Based on the acetaminophen flux measured in our 
studies, inclusion of cetrimide in the peptide formulation produced a ~two-fold increase in EO inhibition 
as compared to iontophoresis of vapreotide alone; furthermore, it may also accumulate in the transport 
pathways impeding vapreotide passage.  Post-iontophoretic treatment methods were investigated with 
the aim of displacing bound peptide from the skin.  However, almost negligible amounts of the peptide 
(<20 ng/cm2) were released after 8 hours post-iontophoretic treatment with the different cationic 
species tested. 
Taken together, these results indicate that the strategies employed to modify skin-vapreotide 
interactions in order to improve peptide delivery were unsuccessful. 
Can therapeutic amounts of vapreotide be delivered? 
To compare our in vitro vapreotide transport studies with the earlier in vivo investigation 
conducted by Lau et al. into the transdermal iontophoresis of octreotide [13], the final set of 
permeation experiments were conducted without a salt bridge and with BSA in the receptor 
compartment.  The amount of vapreotide reaching the receptor compartment after 4, 6 and 8 hours of 
iontophoretic current application (0.15 mA/cm2) are shown in Figure 7.   
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Figure 7. Cumulative amount of vapreotide present 
in the receptor compartment after 4, 6, and 8 hours 
of iontophoretic delivery at 0.15 mA/cm2 across 
porcine epidermis.  
 
 
 
These cumulative quantities were used to estimate the vapreotide flux at 7 hours (1.7 
mg/cm2/h).  Since the experimental conditions chosen for the in vitro study were similar to those used 
by Lau et al. for the iontophoretic delivery of octreotide acetate in the rabbit, a comparison of the 
transport of these two somatostatin analogues is feasible.  After 8 hours of iontophoresis at 0.15 
mA/cm2, the plasma concentrations of octreotide were 0.85 and 1.7 ng/mL with donor concentrations 
of 2.5 and 5 mg/mL, respectively [13].  Based on our vapreotide data (donor concentration of 3 mM @ 
3.9 mg/mL) and the relationship equating flux to plasma concentration (Steady state flux · Area = 
Clearance · [plasma]), it is possible to estimate the plasma concentration of vapreotide if it were 
delivered to the rabbit under similar conditions (assuming the same clearance of 2.3 L/h); the 
estimated value is 0.7 ng/mL, suggesting a slightly lower transport for vapreotide than for octreotide.  
Aside from the subtle differences in amino acid sequence, this might be due in part to (i) the different 
skin models used in the two studies (rabbit skin is recognised as being more permeable than porcine 
skin) and (ii) the above-mentioned differences in metabolic activities (both inter-species and in vitro/in 
vivo).   
Given a total vapreotide clearance of 16.7 L/h in humans (personal communication), an input 
rate of ~25 mg/h must be achieved in order to maintain a therapeutic level of 1.5 ng/mL.  In view of the 
experimental in vitro flux (1.7 mg/cm2/h), it follows that a patch of ~15 cm2 could achieve the desired 
delivery kinetics.  Moreover, given the modest experimental conditions used in this preliminary study, 
the enhancement of vapreotide delivery by further fine-tuning of the formulation and current profile is a 
realizable goal.  For example, the results obtained with a salt bridge system clearly demonstrate that 
vapreotide transport can be enhanced by reducing the number of extraneous ions.  Hence, based on 
the data presented here, the transdermal iontophoretic delivery of therapeutic amounts of vapreotide 
certainly appears to be feasible. 
CONCLUSIONS 
As with the LHRH analogues, nafarelin and leuprolide, and other non-peptidic compounds that 
possess a structural motif characterized by the close proximity of charge and lipophilicity (e.g., 
propranolol and quinine), vapreotide has been shown to interact with the skin membrane.  The degree 
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of electroosmotic inhibition increased with increasing current density.  As a consequence of this 
interaction, and perhaps the aggregation of the peptide, large quantities of vapreotide were found in 
the skin.  The pre-treatment strategies to saturate the skin binding sites and the post-treatment 
methods to displace bound vapreotide proved ineffective.  It was also shown that significantly greater 
amounts of peptide were transported across heat-separated epidermis than across dermatomed skin.  
Vapreotide was susceptible to a significant degree of metabolism (~60-70%) when placed in contact 
with the interior surface of heat-separated epidermis or dermatomed skin.  Given its susceptibility to 
enzymatic degradation, and its capacity to shut down electroosmotic solvent flow, vapreotide may not 
appear as an ideal candidate for transdermal iontophoresis.  Nevertheless, analysis of the cumulative 
amounts permeated across the epidermis and the human pharmacokinetics, suggests that 
iontophoretic delivery might be an effective alternative to the conventional parenteral administration of 
vapreotide. 
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Résumé 
La faisabilité de l’administration transdermique de la triptoréline ([D-Trp6]LHRH) par 
ionophorèse a été évaluée in vitro.  Le transport du peptide a été mesuré à travers la peau d’oreille de 
porc avec différentes concentrations du compartiment donneur, à différentes densités de courant.  
L’administration concomitante d’un marqueur de l’électroosmose a permis de déterminer les 
contributions respectives de l’électromigration et de l’électroosmose au transport ionophorétique.  A 
une concentration donnée (3mM), une augmentation de la densité de courant d’un facteur de trois 
produit une augmentation correspondante de la quantité de peptide présente dans le compartiment 
récepteur.  Inversement, le doublement de la concentration à 6 mM produit une réduction de la 
quantité de peptide administré, en partie en raison d’une inhibition concentration - dépendante de 
l’électroosmose.  L’électromigration se révéla être le mécanisme de transport prédominant, comptant 
pour 80% de l’administration totale.  Finalement, en dépit de l’inhibition de l’électroosmose, les 
résultats indiquent que l’application d’un courant ionophorétique de 0.8 mA sur une surface 
relativement petite (4 cm2) permettrait d’atteindre un taux d’administration excédant 35 mg/h, 
largement supérieur aux exigences thérapeutiques. 
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Abstract 
The feasibility of delivering triptorelin ([D-Trp6]LHRH) by transdermal iontophoresis was 
evaluated in vitro.  Peptide electrotransport at different current densities and donor concentrations was 
measured across porcine ear skin.  The concomitant delivery of an electroosmotic marker enabled 
calculation of the respective contributions of electromigration and electroosmosis to iontophoretic 
delivery.  At a given concentration (3 mM), a three-fold increase in current density produced a 
corresponding increase in the cumulative amount of peptide present in the receptor compartment.  
Conversely, doubling the concentration to 6 mM produced a two-fold reduction in the amount of 
peptide delivered, partly due to a concentration-dependent inhibition of electroosmosis.  
Electromigration was revealed to be the predominant transport mechanism, accounting for 80% of 
overall delivery.  Finally, despite the inhibition of electroosmosis, the results indicate that application of 
an iontophoretic current of 0.8 mA over a relatively small contact area (4 cm2) would provide a delivery 
rate exceeding 35 mg/h, largely sufficient for therapeutic requirements. 
Keywords:  transdermal iontophoresis, triptorelin, electroosmosis 
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INTRODUCTION 
Transdermal delivery has been proposed as a route for administering peptide and protein 
therapeutics on the grounds that it offers a viable alternative to the conventional, and inconvenient, 
administration by parenteral injection.  However, given that peptides are often charged and of high 
molecular weight, their passive transdermal delivery is not feasible.  Hence, different strategies have 
been developed to overcome the skin’s excellent barrier properties in a transient and reversible 
fashion [1;2].  Iontophoresis offers the advantage of providing a controlled and non-invasive delivery 
method that has been extensively investigated [3].  The two main transport mechanisms during 
iontophoresis are electromigration (EM; direct effect of the applied electric field on the charged 
species) and electroosmosis (EO; convective solvent flow in the anode-to-cathode direction, as a 
consequence of the skin’s net negative charge at physiological pH).   
A distinguishing feature of iontophoresis is that, in contrast to other enhancement technologies, 
it acts primarily on the molecule itself.  That is, enhanced delivery is not due to increased passive drug 
transport subsequent to barrier disruption: the driving force is supplied by the applied electric field.  
Furthermore, iontophoresis enables customized therapy: the drug input rate can be adapted to the 
individual needs of each patient, or to the phase of treatment in response to disease progression, by 
modulating the intensity of the applied current.  In addition, different permutations of the current profile 
enable continuous or pulsatile delivery and other more complex drug input profiles, e.g., drug input at 
a basal rate followed by an “on-demand” bolus as in patient-controlled analgesia.   
Control over the input profile is particularly valuable for drugs that have different 
pharmacological effects depending on their input rate, such as luteinising hormone-releasing hormone 
(LHRH) and human parathyroid hormone (PTH).  For example, pulsatile administration of LHRH, 
every 60-90 minutes, is used in the treatment of female infertility due to hypothalamic hypogonadism 
[4], in order to stimulate gonadotrophin release.  In contrast, prolonged continuous application of 
LHRH, and its analogues, suppresses gonadotrophin secretion and is the underlying mechanism in 
the therapy of hormone-dependent cancers [5]. 
Several studies investigating the iontophoretic transdermal transport of LHRH and its more 
potent and longer-acting analogues have been conducted [6-11].  Some of the most relevant results 
were obtained with [D-Leu6,Pro9-NHET]LHRH (leuprolide, LupronÔ), which was successfully delivered 
in vivo in humans: a peak LH response similar to that obtained with subcutaneous injection was 
measured after iontophoretic delivery of leuprolide [12].  Interestingly, these results were accompanied 
by some unexpected behaviour, not consistent with theory: namely, that increasing the dose did not 
result in enhanced delivery [8;13].  Similar findings have been described for other LHRH analogues 
and have been attributed to the association of the lipophilic cations with the membrane, neutralizing 
the intrinsic negative charge of the skin and leading to a significant reduction in the electroosmotic 
transport of the peptide [10;14]. 
The aim of this study was to evaluate the feasibility of delivering triptorelin ([D-Trp6]LHRH, 
DecapeptylÒ) by transdermal iontophoresis and to investigate the transport mechanisms involved.  Co-
iontophoresis of acetaminophen was used to deconvolve the contributions of EO and EM and to report 
on the impact of triptorelin iontophoresis on skin permselectivity.  The effect of current density and 
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peptide donor concentration on delivery was assessed.  Triptorelin transport was also compared to 
that of a tripeptide (Ac-D-Trp-Leu-Arg-NH2) corresponding to its sequence at positions 6-8. 
MATERIALS AND METHODS 
Chemicals 
Triptorelin (MW = 1311.5) pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2, in the form of the 
acetate salt was a generous gift (Debiopharm Galenic Unit, Switzerland). Ac-Tyr-(D-Trp)-Lys-NH2 and 
Ac-(D-Trp)-Leu-Arg-NH2 were custom-synthesised (NeoMPS SA, France).  De-ionized water 
(resistivity > 18 MOhm/cm2) was used to prepare all solutions. 
Analytical procedures 
Triptorelin was quantified by high-performance liquid chromatography.  The HPLC system 
comprised a pump (Waters 600E System Controller, Waters Corporation, MA), dual wavelength UV 
detector (Waters 2487 Dual l Absorbance Detector), autoinjector (Waters 717plus Autosampler) and 
was equipped with a C18 PartiSphere column (4.6 mm i.d., 12.5 cm long, 5 mm particle size) 
(Whatman Inc., NJ) maintained at 40°C.  The mobile phase (25% acetonitrile and 75% 
triethylaminephosphate buffer solution pH 2.3) delivered at a flow rate of 1 mL/min was degassed in-
line (Waters In-Line Degasser AF).  Triptorelin was detected at 280 nm.  The repeatability was less 
than 1 % and the quantification limit was 130 ng/ml. The tripeptides were analysed using the same 
conditions but with a mobile phase consisting of acetonitrile: triethylaminephosphate buffer, pH 2.3 
(12:88).  The repeatability was less than 1 % and the quantification limit was 55 ng/ml. 
Acetaminophen was assayed by high-performance liquid chromatography using a Hypersil BDS 
C8 column (150 mm x 4.6 mm, SupelcoÒ, Sigma-Aldrich Chimie Sarl, France) maintained at 40°C.  
The mobile phase (92% water and 8% acetonitrile adjusted to pH 3.5 with acetic acid) was delivered 
at a flow rate of 1 mL/min.  Acetaminophen was detected by its UV-absorbance at 243 nm.  The 
repeatability was less than 1 % and the quantification limit was 22 ng/ml. 
Skin preparation 
Porcine ears were obtained from the local abattoir shortly after sacrifice.  After cleaning under 
cold running water, the whole skin was removed carefully from the outer region of the ear and 
separated from the underlying cartilage with a scalpel.  Given that epidermis is a well-established 
model for transdermal drug delivery, and that dermatomed skin might act as an artifactual reservoir 
and binding site [15-17], all experiments with triptorelin were performed using heat-separated 
epidermis [18].  Pieces of fresh full-thickness skin were immersed in water at 58°C for 2 minutes after 
which the epidermis was carefully separated from the dermis, wrapped in Parafilmä and maintained at 
–20°C for no longer than a period of 2 months before use.  
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Stability experiments 
The susceptibility of triptorelin to degradation by porcine skin enzymes was assessed in the 
following manner.  Epidermal sections were mounted in diffusion cells and the receptor compartment 
was filled with a 5 mM triptorelin solution, in 25 mM Tris/TrizmaÒ HCl-buffered (pH 7.4) normal saline; 
both the anodal and cathodal compartments were filled with 1 mL of 25 mM Tris/TrizmaÒ HCl-buffered 
(pH 7.4) normal saline.  The concentration of intact triptorelin in the receptor compartment was 
determined after application of a 0.15 mA/cm2 current for eight hours. 
Iontophoresis 
The skin was mounted in three-compartment vertical diffusion cells (area: 0.73 cm2), the design 
of which has been described in detail elsewhere [19].  Except in the case of the stability experiments, 
the anode was isolated from the donor solution via a salt bridge (100 mM Tris/Trizma HCl in 3% 
agarose) to minimize competition between the peptide and the electrolytes necessary for the anodal 
reaction.  Anodal, cathodal and receptor compartments contained a solution of 25 mM Tris/TrizmaÒ 
HCl normal saline buffered to pH 7.4.  Triptorelin (3 mM unless otherwise stated) was solubilized in 20 
mM Tris/TrizmaÒ HCl  (pH 7.4).  In addition to the peptide, the donor compartment (1 mL) always 
contained 15 mM acetaminophen. 
Constant current iontophoresis was used in all the experiments.  The current, ranging from 0.15 
to 0.5 mA/cm2 was applied for 4 to 8 hours via Ag/AgCl electrodes connected to a power supply 
(Kepco, NJ). 
Quantification of electroosmotic solvent flow  
Acetaminophen is a neutral hydrophilic compound, which is primarily transported through the 
skin by electroosmosis.  It was therefore included in the donor compartment formulation (15 mM) as a 
marker for the magnitude of convective flow (15 mM).  For each experiment, an Inhibition Factor (IF) 
was calculated according to the following equation: 
IF = [QA-8h,control] / [QA-8h,peptide] (1) 
where QA-8h,control is the amount of acetominaphen transported into the receptor phase during 8 hours 
of iontophoresis when no peptide was present in the donor solution, and QA-8h,peptide is the 
corresponding quantity when triptorelin was iontophoresed.. 
Effect of current density and triptorelin concentration 
To evaluate the effect of current density on both triptorelin transport and inhibition of 
electroosmosis, current densities of 0.15, 0.3 and 0.5 mA/cm2 were applied for 8 hours using a donor 
peptide concentration of 3 mM. 
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The iontophoretic delivery of a higher concentration (6 mM) at 0.5 mA/cm2 for 8 hours was also 
investigated to determine the impact of the donor concentration on the electroosmotic flow and overall 
peptide transport. 
Data treatment 
All measurements were performed in at least triplicate, using skin samples originating from 
different pig ears.  Outliers, determined using the Grubbs test, were discarded. 
RESULTS AND DISCUSSION 
Triptorelin stability in the presence of skin 
Investigation of the in vitro stability of triptorelin in the presence of epidermis revealed a 
degradation of 9 ± 2% after 8 hours, suggesting that it was quite resistant to proteolysis.  Peptide 
susceptibility to enzymatic degradation is obviously dependent on the amino acid sequence: under the 
same conditions, again using porcine epidermis, the somatostatin analogue, vapreotide, suffered 
significantly greater metabolism (68 ± 11%) [17].  Amidation of the C-termini ensures that both 
peptides are protected against carboxypeptidases.  The cyclic pGlu and D-Phe residues at the N-
termini protect triptorelin and vapreotide, respectively, against aminopeptidase activity.  Thus, 
endopeptidases or reductases targeting the disulphide bridge, present in vapreotide, but not in 
triptorelin, might also be active in the skin. 
Triptorelin delivery and the effect of current density  
The quantities of triptorelin transported across porcine epidermis from a 3 mM donor solution 
after 4, 6 and 8 hours of iontophoresis (at a current density of 0.5 mA/cm2) are depicted in Figure 1.   
Figure 1. Cumulative transport of triptorelin across 
porcine skin in vitro following iontophoretic current 
application at 0.5 mA/cm2 for 4, 6 and 8 hours, 
respectively.  The formulation in the donor compartment 
comprised 3 mM triptorelin in 20 mM Tris/Trizma at pH 
7.4. 
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After 8 hours of iontophoresis, 120 ± 30 mg/cm2 of triptorelin was detected in the receptor 
compartment, with an estimated flux of 22 mg/cm2/hr at 7 hours.  The iontophoretic transport rate of [D-
Trp6,Pro9-NHET]LHRH, which has almost complete sequence homology with triptorelin ([D-
Trp6]LHRH), across hairless mouse skin in vitro was very similar (17 mg/cm2/hr) at the same current 
density (0.5 mA/cm2) and donor concentration (3 mM) [7].  Although iontophoretic delivery of triptorelin 
across human and rabbit skins has been reported [11], quantitative comparison is rendered difficult by 
the differences in experimental conditions and the variability of the data. 
The iontophoretic flux (J) of a charged species is the sum of two transport mechanisms - 
electromigration (JEM) and electroosmosis (JEO), assuming that passive diffusion is negligible: 
EOEM JJJ +=  (2) 
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According to Faraday’s law, JEM is related to the applied current density (I), to the transport number 
(t#), electrical mobility (u), charge (Z), and concentration (c) of the drug, and to the concentrations, 
mobilities and charges of the other ions present in the system (ci, ui, zi).  Since the electroosmotic flow, 
from anode-to-cathode under physiological conditions, increases with applied current density [20], 
both transport mechanisms, and hence the total iontophoretic flux, are related to the applied current.  
This is illustrated by the data in Table 1 which show that a three-fold increase in current density (0.15 
to 0.5 mA/cm2) resulted in a corresponding increase in the cumulative amount of triptorelin in the 
receiver compartment (35 ± 9 to 120 ± 30 mg/cm2).   
Table 1. Effect of current density on the iontophoretic transport and electroosmosis inhibition of triptorelin (3 mM). 
Current density 
[mA/cm2] 
Triptorelin transport 
[mg/cm2] 
Inhibition 
factor 
 0.15            35 ± 9 1.0 ± 0.8 
0.3  60 ± 30 3.6 ± 1.8 
0.5          120 ± 30 6 ± 3 
 
In contrast, the increase in current produced a sharp decrease in acetaminophen transport; a six-fold 
reduction was observed at 0.5 mA/cm2, indicative of considerable EO inhibition. 
Linear correlations between flux and current density have been reported for non-peptidic 
compounds as well as for small peptides (e.g., TRH [21] and Threo-Lys-Pro [22]).  For larger peptides, 
although an increased current density usually results in increased permeation, straightforward linear 
correlations are not always observed.  For example, a poor correlation was observed between DGAVP 
(9-desglycinamide, 8-arginine-vasopressin) flux and applied current; a more than six-fold increment in 
current density did not even double the flux [23].  However, it was shown that increasing the applied 
current density from 0.1 to 0.5 mA/cm2 produced an almost 3-fold increase in the flux of the 
structurally-related peptide [D-Trp6,Pro9-NHET]LHRH [7]. 
Chapitre 5  88 
 
 
Contributions of electromigration and electroosmosis to triptorelin transport 
Since acetaminophen is a neutral hydrophilic molecule with negligible passive skin permeability, 
its iontophoretic transport is almost exclusively due to electrically-induced convective solvent flow and, 
as such, its transport can be used to report on electroosmosis. During iontophoresis, the velocity (Vw) 
of the current-induced water flow (units of cm/h, equivalent to a permeability coefficient) across the 
skin can be estimated using equation 4 [24]:  
Vw  =  Jace/Cace    (4) 
where Jace and Cace are the flux and donor concentration of acetaminophen, respectively.  It follows 
that a measurement of Jace at known Cace allows Vw to be determined.  It is then possible to calculate 
the EO contribution to the flux of the peptide by multiplying Vw by its concentration in the donor 
solution (Cpeptide) [25]: 
JEO  =  Vw∙Cpeptide (5) 
Two assumptions are implicit in this analysis: (a) that drug and acetaminophen are transported 
in a similar fashion by convective solvent flow, and (b) that electroosmotic transport of the marker 
molecule is proportional to its concentration in the solvent.   
Co-iontophoresis of acetaminophen (15 mM) with triptorelin (3 mM) at 0.5 mA/cm2, for 8 hours, 
resulted in an acetaminophen flux of 18 nmol/cm2/h; this was used to calculate Vw using Equation 4.  
The quantity of triptorelin transported by electroosmosis could then be estimated by substitution of Vw 
(1.2x10-3 cm/h) into Equation 5.  Given the measured total flux of triptorelin under the same conditions 
(17 nmol/cm2/h), Equation 2 allows assignment of the relative contributions of EO and EM to the total 
iontophoretic flux.  The analysis reveals that EM is the dominant transport mechanism for triptorelin, 
accounting for ~ 80% of overall transport (JEO = 3.6 nmol/cm2/h; JEM = 13.4 nmol/cm2/h).  It is worth 
noting that in the absence of any inhibition, the maximum theoretical EO contribution (JEO,max, that is, 
assuming Vw ~ 4.8x10-3 cm/h) to the iontophoretic delivery of triptorelin (3mM at 0.5 mA/cm2) would 
only be ~14 nmol/cm2/h; implying that for this decapeptide (MW ~1311), EM would still account for 
~50% of iontophoretic transport. 
Acetaminophen transport in the presence of triptorelin clearly demonstrated that the latter 
inhibited EO (IF of 6 ± 3), albeit to a much lesser extent than certain other peptides.  For example, 
vapreotide iontophoresis under equivalent conditions resulted in an IF of 50 ± 30 [17].  Vapreotide is 
doubly charged (due to the lysine side chain and the free N-terminal) and this probably favours the 
interaction with negatively charged sites in the skin and accounts for its greater propensity to inhibit 
EO.  Furthermore, the presence of a disulphide bridge in vapreotide probably contributes to a more 
compact three-dimensional structure than triptorelin; the preferred conformations may orient the key 
moieties so as to favour interaction with the skin’s binding sites, and hence facilitate EO inhibition.   
Are peptide fragments useful predictors of transport ? 
Nafarelin ([D-Nal(2)6]LHRH) and the tripeptide (D-Nal(2))-Leu-Arg (representing the amino acids at 
positions 6 to 8) were demonstrated to be equipotent EO inhibitors [14].  In contrast, while triptorelin 
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caused EO inhibition (IF = 6 ± 3), co-iontophoresis of its “peptide motif” Ac-(D-Trp)-Leu-Arg-NH2 with 
acetaminophen failed to result in a corresponding effect (IF = 1.1 ± 0.2) (Figure 2). 
 
Figure 2. Inhibition factors of triptorelin, vapreotide and their constituent tripeptides after iontophoretic current 
application at 0.5 mA/cm2 for 8 hours.  The formulation in the donor compartment comprised 3 mM peptide in 20 
mM Tris/Trizma at pH 7.4. 
 
Iontophoresis of the tripeptide Ac-Tyr-(D-Trp)-Lys-NH2, derived from the residues at positions 3 to 
5 in vapreotide, under the same experimental conditions, also produced almost no inhibition of EO (IF 
= 1.5 ± 0.5) compared to the parent peptide (IF = 50 ± 30) [17].  Hence, the occurrence and extent of 
this phenomenon cannot, as a rule, be accurately predicted from the behaviour of the structural motif 
presumed responsible for the skin interaction.  It should be noted that interspecies differences (the 
triptorelin and vapreotide studies were conducted with porcine skin whereas nafarelin and (D-Nal(2))-
Leu-Arg data were obtained using hairless mouse skin) may also play a role in the interpretation of 
mechanistic data.  This is further illustrated by the observation that the dependence of iontophoretic 
propranolol delivery on donor concentration (in the presence of competing ions), across these two 
membranes, is different [25]. 
Effect of increasing triptorelin concentration on peptide transport and electroosmosis 
The impact of drug concentration on iontophoretic flux is a commonly studied experimental 
parameter.  According to Equation 3, an increase in the formulation’s drug-load should result in an 
increase in the EM component and hence in the total drug flux (with the assumption that the 
formulation concentration is equivalent to that present in the supposed aqueous transport pathways 
within the membrane).  Indeed, when the donor formulation contains background electrolyte, a source 
of competing ions, the initial linear dependence that is observed between flux and drug concentration 
dwindles as concentration increases: once the product of the drug concentration and mobility (see 
Equation 3) is in sufficient excess of the corresponding values for the competing ions, the flux 
becomes independent of drug concentration.  Triptorelin contains the (D-Trp-Leu-Arg) sequence at 
positions 6 to 8 in its primary structure; this sequence corresponds to the oligopeptide motif 
(hydrophobe-hydrophobe-cation) hypothesized to be responsible for the “anomalous” iontophoretic 
behaviour observed with nafarelin, leuprolide and octreotide upon increasing the donor concentration.  
In a second series of transport experiments with twice the triptorelin concentration (6 mM) in the donor 
compartment, only 60 ± 40 mg/cm2 of triptorelin was measured in the receptor compartment, compared 
to 120 ± 30 mg/cm2 with the lower donor concentration (3 mM); a two-fold increase of peptide in the 
formulation produced a two-fold decrease in delivery.  The simultaneous administration of 
acetaminophen as an electroosmotic marker, allowed the inhibition factor to be calculated.  The IF 
Triptorelin p Glu His Trp Ser Tyr D -Trp Leu Arg Pro Gly NH2   6 +/- 3
Ac- D -Trp Leu Arg NH2   1.1 +/- 0.2
Vapreotide D -Phe Cys Tyr D -Trp Lys Val Cys Trp NH2 50 +/- 30
Ac- Tyr D -Trp Lys NH2   1.5 +/-   0.5
Inhibition factor
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values at 3 and 6 mM triptorelin concentrations were 6 ± 3 and 10 ± 5, respectively, substantiating the 
inhibitory effect of this peptide on the convective solvent flow.  However, given that EO accounted for 
only ~20% of iontophoretic transport at a donor concentration of 3 mM, the increased EO inhibition 
cannot alone explain the two-fold reduction in the cumulative amount delivered: the increase in donor 
concentration must also impact on EM.  Hence, it seems likely that other interactions, perhaps 
involving the formation of triptorelin aggregates, which would hinder peptide delivery, must occur 
within the transport pathways. 
The separate effects of aggregation and inhibition could be represented by modification of 
Equation 2: 
( ) INHIBNOEOPREDEMEXPT JJJ  )1(1 ba -+-=  (6) 
where a and b represent the degree of aggregation and EO inhibition, respectively.  
Increasing aggregation would reduce drug mobility and predominantly affect EM; b, which is 
proportional to IF, would negatively impact upon convective solvent flow.  Thus, peptide accumulation 
could occur without affecting EO.  At the same time, peptides could strongly inhibit EO and still have 
that as the major transport mechanism, if they also exhibit a high degree of aggregation. 
Can therapeutic amounts of triptorelin be delivered by transdermal iontophoresis? 
The “bottom line” of any feasibility study with a therapeutic molecule is to determine whether 
sufficient drug can be delivered to achieve the desired pharmacological effect.  For triptorelin, the 
plasma concentration required for biochemical castration is ~1.7 nmol/L (equivalent to ~2.2 ng/mL) 
[26].  Given that the total body clearance in healthy individuals is ~200 mL/min [27], the target input 
rate that must be achieved to maintain the steady state triptorelin concentration necessary for durable 
biochemical castration is ~26 mg/h.  The measured triptorelin flux of 22 mg/cm2/h (at 7 hrs) signifies 
that, at the current density used in these experiments (0.5 mA/cm2), it would be entirely feasible to 
deliver therapeutic levels of triptorelin with a patch application area of less than 2 cm2.  As reported 
above, triptorelin delivery increases essentially linearly with current; hence, the measured peptide flux 
can be normalized by the applied current density to obtain a measure of mass transport per unit 
current per unit time; the “current-normalized” flux for triptorelin is 45 mg/mA/h.  A current density of 0.5 
mA/cm2 is at the upper limit of the range generally considered acceptable for human use, and is 
probably unsuitable for prolonged application.  The “current-normalized” flux can be used to calculate 
the application area necessary to deliver therapeutic amounts of triptorelin at lower, and better 
tolerated, iontophoretic current densities.  For example, the application of a 0.8 mA iontophoretic 
current over a 4 cm2 contact area, equivalent to a far more acceptable current density of 0.2 mA/cm2, 
would be sufficient to provide a delivery rate exceeding 35 mg/h.  
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CONCLUSIONS 
These preliminary in vitro studies illustrate the contrasting effects of current density and 
triptorelin concentration on delivery.  At a given concentration (3 mM), a three-fold increase in current 
density produced a corresponding increasing in the cumulative amount of peptide transported across 
porcine epidermis.  Conversely, doubling the concentration to 6 mM produced a two-fold reduction in 
the amount of peptide delivered following iontophoresis for 8 hours at 0.5 mA/cm2.  Although theory 
would suggest equivalent effects upon increasing current or concentration, the experimental results 
reveal that this is not always the case.  Thus, formulation parameters must be carefully selected to 
optimize the delivery of complex molecules.  Quantification of acetaminophen transport in the 
presence of triptorelin revealed that EM was the predominant transport mechanism, accounting for 
~80% of overall delivery.  The acetaminophen data also revealed that triptorelin was capable of a 
concentration-dependent EO inhibition.  Nevertheless, the degree of inhibition was insufficient to 
explain the inverse dependence of transport on peptide concentration, suggesting the involvement of 
peptide aggregation.  Despite the EO inhibition and putative aggregation phenomena, the cumulative 
amount of triptorelin delivered and the estimated iontophoretic flux suggest that drug input rates 
sufficient to achieve plasma levels capable of ensuring prolonged biochemical castration may be 
attainable using transdermal iontophoresis. 
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L’étude portant sur l’administration du vapréotide illustre la fonction barrière métabolique 
qu’exerce la peau en plus de sa fonction barrière physique plus évidente.  La forte susceptibilité de cet 
analogue de la somatostatine vis-à-vis de la dégradation enzymatique ainsi que son importante 
capacité à inhiber l’électroosmose, et par là même son propre transport, font de ce peptide un 
candidat non idéal à l’administration transdermique par ionophorèse.  Si les résultats obtenus 
indiquent qu’un patch de 15 cm2 pourrait tout de même permettre d’atteindre des concentrations 
thérapeutiques, les flux mesurés pour la triptoréline sont nettement plus importants, notamment en 
raison de sa faible dégradation enzymatique.  Cet analogue de la LHRH s’avère donc être un bien 
meilleur candidat et son administration par ionophorèse semble à même d’offrir une alternative aux 
formes médicamenteuses actuellement disponibles.  Des expériences conduites in vivo avec ces deux 
peptides fourniraient des informations supplémentaires permettant de mieux anticiper les corrélations 
in vitro - in vivo dans le cas de molécules comme celles-ci, notamment en termes de dégradation 
enzymatique.  Elles pourraient valider les flux estimés et ainsi constituer un pas décisif vers 
l’administration transdermique de peptides thérapeutiques par ionophorèse. 
Alors que ces deux peptides ont montré leur capacité à inhiber l’électroosmose (inhibition 
suspectée par leur structure présentant un acide aminé chargé près d’un groupement lipophile), 
l’étude du comportement ionophorétique des tripeptides correspondant à cette séquence clé révéla 
que l’inhibition induite par un peptide ne peut être prédite sur la base de l’inhibition exercée par le 
tripeptide présentant la juxtaposition « charge et lipophilie ».  Ceci démontre bien la complexité de 
l’interaction avec la membrane et met en évidence le manque de connaissance actuel sur les 
éléments structuraux influençant les mécanismes de transport en ionophorèse.  
L’étude systématique menée sur une série de tripeptides dont la séquence est dérivée de 
celle des analogues de la LHRH et de la somatostatine, a permis de mettre en évidence des 
propriétés moléculaires-clé intervenant dans le passage transdermique de ces composés par 
ionophorèse.  L’hydrophobie est apparue comme paramètre déterminant, s’opposant au passage des 
peptides.  Si il a été montré qu’elle favorise l’inhibition de l’électroosmose, elle semble impliquée dans 
d’autres interactions ayant pour conséquence de restreindre le transport.  En montrant que non 
seulement le volume des régions hydrophobes mais également leur distribution au sein de la molécule 
ont un impact sur le transport, cette approche computationnelle a démontré qu’il est essentiel de 
prendre en considération l’environnement tridimensionnel des composés.  Elle a ainsi permis de 
mettre en évidence la différence de lipophilie pouvant exister entre deux tripeptides constitués des 
mêmes acides aminés mais arrangés selon un autre ordre, différence qui s’est manifestée au niveau 
de leur transport ionophorétique.  Des interactions telles que celles existant entre les chaînes latérales 
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des acides aminés sont susceptibles d’influencer la conformation tridimensionnelle, modulant ainsi la 
lipophilie du peptide, ce qui ne peut être détecté par une méthode fragmentale bi-dimensionnelle telle 
que le ClogP.  Cet effet de la séquence en acides aminés sur le transport ionophorétique mérite d’être 
plus amplement étudié.  La ionophorèse de peptides supplémentaires ainsi que la mise en évidence 
expérimentale de cette différence de lipophilie par des mesures de voltamétrie cyclique peut en effet 
être envisagée.  Il serait par ailleurs intéressant de confirmer l’effet du type de charge observé lors de 
la comparaison du transport des peptides contenant la lysine à ceux dont la charge est fournie par 
l’arginine. 
Enfin, il serait particulièrement profitable d’étayer le modèle établi puis de l’élargir à d’autres 
molécules, ce qui permettrait notamment d’approfondir les connaissances actuelles des mécanismes 
de transport impliqués dans l’administration transdermique par ionophorèse.  Aussi, on pourrait 
imaginer qu’une telle approche permette un jour d’évaluer la faisabilité de l’administration d’un 
candidat médicament par cette technologie, sans expérimentation in vitro, voire même avant la 
synthèse du composé.  
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